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Abstract 
One of the primary mechanisms of antibiotic resistance in bacteria stems from 
the expression of multicomponent efflux transporters, located in the membranes of 
both Gram-positive and Gram-negative bacteria. Although these transporters are 
divided into different families, many are dependent on membrane fusion proteins 
(MFPs). MFPs are thought to provide a functional linkage between the inner and 
outer membrane components of the complex in Gram-negative bacteria. However, 
these proteins have also been found in Gram-positive organisms, indicating a role 
beyond that of simply providing a link between transporter components. MFPs have 
since been shown to have diverse functions such as transporter stimulation and 
recruitment of outer membrane components. The extent to which MFPs participate 
in the transport reaction is still unclear. Also, the manner through which MFPs 
associate with their cognate inner membrane transporters (IMFs) and outer 
membrane channels (OMFs) is undefined. Furthermore, the details of MFP 
oligomerization and interaction with transporter components are unknown, leaving 
the picture of MFP-dependent transport incomplete. 
This dissertation focuses on two unique MFP-dependent transporters. The first, 
TriABC-OpmH from Pseudomonas aeruginosa, is a paired-MFP transporter. 
TriABC relies on the two MFPs TriA and TriB in order for the resistance-
nodulation division (RND) type transporter TriC to function with OpmH, an OMF. 
We constructed a functional, fused protein comprised of TriA and TriB. We also 
created deletion and point mutants of TriA and TriB, and analyzed the function and 
assembly of these mutants. Our functional genetic and biochemical studies 
xii 
demonstrate that the functional unit of the MFP is a dimer, and that TriA and TriB 
occupy different binding sites on both the TriC transporter and OMF. These results 
suggest that TriA and TriB have non-equivalent roles in the transport process, and 
that one protomer in the MFP dimer may be responsible for interactions with the 
OMF such as recruitment and substrate export, and the other interacts primarily with 
the IMF and is responsible for functions such as transporter stimulation. We propose 
that these findings also apply to transporters utilizing a single MFP, which 
oligomerize to form homodimers, rather than heterodimers.  
The second MFP-dependent transporter discussed is the four-component 
YknWXYZ from the Gram-positive bacterium Bacillus subtilis. Here, the MFP 
YknX functions in tandem with the ABC-type transporter YknYZ and a protein of 
unknown function, YknW. Gram-positive bacteria have no outer membrane, making 
the presence of an MFP puzzling. To determine the function of an MFP in a Gram-
positive cell envelope, we created chimeric fusion proteins between YknYZ and the 
homologous E. coli transporter MacB, and we attempted to analyze the stimulatory 
activities of YknX. We also purified different components of the YknWXYZ 
transporter to determine ATPase activity of the complex. We conclude that 
YknWXYZ is a unique, four-component transporter that warrants further 





Bacterial antibiotic resistance has grown beyond being a rising concern to public 
health and positioned itself as an imminent threat. Currently, resistant species are 
pervasive within all nations. These resistant bacteria actively handicap effective 
treatment of infections that are commonplace in both daily life and clinical settings 
(WHO 2014). Humankind has known about the threat of antibiotic resistance since the 
inception of these drugs. The discoverer of penicillin, Alexander Fleming, warned of 
the possibility of resistance in his Nobel acceptance speech in 1945 (Rosenblatt-Farrell 
2009). The population of drug resistant pathogens has increased significantly in the past 
decade, and the current situation demands that research be focused on antimicrobial 
resistance to ward off a “post-antibiotic era” in which common infections can kill 
simply because no effective antimicrobials exist. (WHO 2014) Bacterial resistance 
mechanisms have developed largely through the misuse of antibiotics in both human 
and animal populations. Exposure to sub-lethal levels of drug removes susceptible 
bacteria from the gene pool, but leaves resistant cells to grow and proliferate, thereby 
raising the basal level of resistance in a bacterial population. An increasing number of 
bacterial strains exhibit resistance towards many structurally unrelated drugs and are 
deemed to be multidrug resistant (MDR). (Nikaido 2009) MDR further reduces clinical 
treatment options for infections by restricting the effective set of antibiotic families. 
(Nikaido and Pages 2012) 
Bacterial antibiotic resistance can either develop intrinsically, or be gained 
through exchange of genes with other bacteria. This exchange occurs through 
transduction, conjugation, and transformation of antibiotic-resistance genes. (Levy and 
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Marshall 2004) The specific mechanisms through which drug resistance is achieved 
include alteration of target proteins, drug inactivation, membrane permeability, and the 
expression of membrane-bound drug efflux pumps (Higgins 2007). Active efflux 
systems are recognized as some of the most clinically relevant mechanisms of antibiotic 
resistance, and expression of these pumps allows for the recognition and expulsion of 
drug from the cell before the concentration of drug reaches an effective level. Many of 
these pumps are promiscuous and able to expel structurally unrelated drugs, leading to 
MDR. (Zgurskaya and Nikaido 2000) As the pipeline of new antibiotics seems to be 
exhausted, targeting efflux pumps is a promising approach in efforts to combat drug 
resistance. 
 
I.1 – Types of bacterial multidrug efflux transporters  
Multidrug resistant transporters are present in all three kingdoms of life, but are very 
well represented in bacteria, making up 2-7% of total protein composition. (Saier and 
Paulsen 2001) Transporters are divided into a number of superfamiles based on 
characteristics such as the utilized energy source, substrate specificity, and accessory 
proteins (Piddock 2006). Efflux complexes are composed of individual protein subunits 
that together are able to utilize energy to bind and extrude substrate from the interior of 
the cell to the extracellular milieu. Currently identified MDR pumps fall into five major 
classes: the ATP-Binding Cassette (ABC) superfamily (Higgins and Linton 2004), the 
Small Multidrug Resistance (SMR) family, which is now a part of the DMT (Drug / 
Metabolite Transporter) superfamily (Chung and Saier 2001), the Major Facilitator 
Superfamily (MFS) (Saier, Paulsen et al. 1998), the Resistance Nodulation Division 
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(RND) family (Tseng, Gratwick et al. 1999), and the Multidrug and Toxic Compound 
Extrusion (MATE) family, which recently joined the MOP 
(Multidrug/Oligosaccharidyl-lipid/Polysaccharide) superfamily) (Jack, Yang et al. 
2001, Hvorup, Winnen et al. 2003). The most relevant class of pumps with respect to 
antibiotic resistance in Gram-negative bacteria is the RND family (Yamaguchi, 
Nakashima et al. 2015). However, pumps of each class have been identified in both 
Gram-positive and Gram-negative bacteria. (Li and Nikaido 2004, Lorca, Barabote et 






Figure I.1 – Efflux pump classes of Gram-positive and Gram-negative bacteria.  
Classes of efflux pumps are diagrammed along with typical substrates. 
 
 ABC-type MDRs are the only primary active transporters, whereas all other 
superfamilies utilize ion gradients to translocate substrate (Li and Nikaido 2004). These 
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ion gradients are normally protons, but occasionally found are sodium ions. 
Independent of classification and energy source, all transporters share at least three 
steps during the transport process. First, substrate must bind to the transport complex. 
Secondly, the substrate must be re-oriented to the opposite side of the membrane, and 
then thirdly, the substrate must be released through a conformational change in the 
binding site of the transporter (Zgurskaya, Weeks et al. 2015). Utilization of energy, 
either through ATP hydrolysis or proton / sodium motive force (PMF) occurs during the 
relaxation step of the transporter to re-orient the binding site to the original resting state 
(Davidson, Dassa et al. 2008, Eicher, Seeger et al. 2014).  
 
I.2 – Mechanisms of ABC and RND-type efflux transporters 
Transporters use a wide range of mechanisms in order to achieve efflux. AcrB, 
of the E. coli AcrAB-TolC complex is the most well-understood RND-type transporter, 
and has been crystallized in many forms, including in complex with substrate. Studies 
of this protein has shed light on the  molecular mechanism of RND-type transporters 
(Murakami, Nakashima et al. 2002, Yu, McDermott et al. 2003, Murakami, Nakashima 
et al. 2006, Sennhauser, Amstutz et al. 2007, Du, Wang et al. 2014). AcrB functions as 
an asymmetric trimeric unit, in which each protomer moves through a three-
conformation cycle, consisting of the open (O), loose (L), and tight (T) states. (Seeger, 
Schiefner et al. 2006) These three conformations differ in how the transporter interacts 
with substrate. The loose conformation is proposed to have an exposed binding pocket 
with a loose binding affinity for substrate. Upon binding, the conformation of the 
protomer switches to the T state, effectively capturing the substrate with a much higher 
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binding affinity in a hydrophobic pocket (Murakami, Nakashima et al. 2006). Finally, 
the conformation switches to the O state, releasing the substrate towards the periplasmic 
side of the membrane for eventual export through other complex components. Resetting 
the O state to the L state restarts the cyclic event, allowing the next substrate to bind. It 
is important to note that the individual monomers do not physically rotate, but rather 
have a conformational rotation. (Pos 2009).  
The individual subunits of RND-type transporters are connected by 
interprotomer loops, and there is considerable flexibility within the trimeric structure, 
indicating an alternating site mechanism (Seeger, Schiefner et al. 2006). Symmetric 
structures of AcrB have also been solved and supported by crosslinking data 
(Murakami, Nakashima et al. 2002, Takatsuka and Nikaido 2007). These structures 
show all three protomers of the trimeric structure in the T or L conformations, 
indicating that the structure exists in a “resting state” in low substrate concentrations, 
and all protomers are available for substrate binding. The binding of substrate to one 
protomer causes a shift from the L to T state, and binding of substrate to an adjacent 
protomer is required for the shift from T to O, and release of the substrate (Yamaguchi, 
Nakashima et al. 2015). The functional rotation mechanism was verified through a 
covalently linked AcrB trimer, in which one monomer was inactivated through 
mutations in the proton relay network, and the complex was rendered nonfunctional 
(Takatsuka and Nikaido 2009). 
Efflux in RND-type transporters is driven by PMF (Zgurskaya and Nikaido 
1999). Specifically, four charged residues are thought to form a proton relay network 
that exists approximately 50 Å away from the drug binding pocket (Murakami, 
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Nakashima et al. 2002, Murakami, Nakashima et al. 2006). The distance between the 
relay network and the binding pocket indicates remote-conformational coupling of 
energy (Yamaguchi, Nakashima et al. 2015). The protonation of the transporter from 
PMF occurs in the periplasm, during the transition between the T and O states. 
Subsequent deprotonation of the transporter occurs during the transition from the O to L 
states, in which the proton is released into the cytoplasm, and the transporter is reset for 
the next transport cycle (Murakami, Nakashima et al. 2006).  
In contrast to RND-type pumps, ABC-type efflux pumps utilize ATP as a 
primary energy source. Correspondingly, their overall structure greatly differs from 
RND-type transporters (Figure I.2). Rather than forming a trimeric transporter, ABC-
type transporters form a homodimer or heterodimer, in which each protomer of the 
dimer contains two domains required for efflux. The nucleotide-binding domain (NBD) 
is known to bind and hydrolyze ATP required for transport, and the transmembrane 
domain (TMD) is the membrane-spanning region of the protein that forms a tunnel 
through the lipid bilayer (Wilkens 2015). To satisfy the requirement of unidirectional 
transport, the TMDs alternate between inward and outward facing conformations, 
effectively forming a gate with different binding affinities for substrate on either side of 
the membrane (Senior, al-Shawi et al. 1995). 
The NBD domains of the transporter each contain three conserved motifs, all 
involved in the binding and hydrolysis of ATP. Firstly, a Walker A motif which is 
involved in the binding of the phosphate groups of ATP. Secondly, the Walker B motif 
which contains a glutamate reside that is known to attack ATP and bind water. Finally, 
the last conserved structure is the ABC signature motif. This contains a signature 
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LSGGQ sequence that is known to contact ATP in the ATP-bound state of the NBD. 
Generally, ABC-type ATPases sandwich two ATP molecules between two ABC half-
domains, in which the Walker A motif of one monomer works with the ABC signature 
motif from the other monomer in order to effectively hold both ATP molecules. (Locher 
2009) The ABC-type MacAB-TolC transporter of E. coli is the most well-studied ABC-
type bacterial drug efflux transporter to date. MacAB-TolC consists of the transporter 
MacB, the membrane fusion protein MacA, and the outer membrane factor TolC. Efflux 
transporters from different families have also been found in Gram-positive bacteria. 
(Freudl 2013) One such transporter, YknWXYZ of B. subtilis, is an ABC-type 
transporter known to provide resistance against an endogenously-produced toxin. 
(Yamada, Tikhonova et al. 2012) 
There are multiple models describing the specific mechanism of ABC-type 
exporters. The common themes among these models are binding of both substrate and 
ATP to the NBD domains, dimerization of the NBD domains, a switch from the inward 
to outward-facing conformations, and ATP hydrolysis combined with a release of ATP, 
inorganic phosphate, and substrate. NBD dissociation also is thought to occur to reset 
the transporter for the next cycle. The differing characteristics of these models lie in the 
order and details of these individual steps. The “switch” model (Higgins and Linton 
2004) shows that the NBD domains dissociate completely at the end of the cycle for 
product release and reset of the transporter. Other models such as the constant contact 
model speculate that the NBDs retain contact through one of the two ATP-binding sites 
and operate in a “seeswing” fashion, so that one nucleotide remains occluded at all 
times (Jones and George 2014, Wilkens 2015). While there are many specifics under 
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debate about how ABC-type transporters move substrate across the membrane (Senior, 
al-Shawi et al. 1995, Higgins and Linton 2004, Siarheyeva, Liu et al. 2010, Jones and 
George 2014) the prevailing theory is that the ATP hydrolysis and release results in 
resetting the transporter back to the pre-translocation state, similar to how the passage 
of protons in RND transporters drives the conformational change back to the L state. 
The transport cycle of both ABC-type and RND-type transporters can be 
summarized in a three-step model, containing the steps consistent between transporters. 
Firstly, the transporter is in an open conformation, allowing binding of substrate. 
Second, substrate binding results in a conformational change that increases affinity of 
the transporter to the substrate. The third and final step of transport results in a re-
orientation of the binding site to the opposite side of the membrane, and a decrease in 
affinity between the substrate and transporter, ultimately releasing the substrate 
(Zgurskaya, Weeks et al. 2015). In the case of Gram-negative organisms, the final step 
passes the substrate on to other complex components, such as the outer membrane 
factor (OMF). 
 
I.3 – Roles of outer membrane factors in transport 
The OMF forms a channel through the outer membrane that facilitates expulsion 
of substrate into the extracellular space, with an opening that can be triggered upon 
interaction with the other transporter components (Lobedanz, Bokma et al. 2007, 
Tikhonova, Dastidar et al. 2009). These channels are trimeric, and typically composed 
of three central domains. A β-barrel is imbedded into the outer membrane, providing 
transmembrane passage for substrate. The periplasmic portion of the channel forms a 
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large α-barrel, made up of bundles of α-helices, which extend into the periplasm from 
the outer membrane and are important for interaction with other transporter 
components. The equatorial domain lies in the central region of the α-barrel, and 
contains both the N- and C-terminus of the protein (Figure I.2) (Zgurskaya, 
Krishnamoorthy et al. 2011). The best-studied OMF, TolC of E. coli, is promiscuous, 
and known to interact with many efflux pumps from many different families, including 
AcrAB (RND), MacAB (ABC), and EmrAB (MF) (Koronakis, Sharff et al. 2000, 
Koronakis, Eswaran et al. 2004).  
Crystal structures of TolC reveal a tight packing of the α-barrel domain, such 
that the periplasmic tip of the channel is tightly closed and unable to allow access to 
molecules as small as ions (Koronakis 2003). Due to this tight packing, the helices of 
the α-barrel are inclined with respect to the axis of the molecule, forming an aperture-
like opening that models suggest undergoes a “twist” in order to open (Andersen, 
Koronakis et al. 2002, Bavro, Pietras et al. 2008, Pei, Hinchliffe et al. 2011). This 
conformational change rotates the helices, and allows an opening of the periplasmic tip, 





Figure I.2 – Typical Gram-negative efflux transporter components. 
Components of a typical Gram-negative efflux transporter include an IMF, in this case 
either a MacB-type ATPase or a typical RND-type transporter that bridges the inner 
membrane, an OMF to bridge the outer membrane, in this case TolC, and an MFP, 
shown here as AcrA. Domains of the OMF are labeled. IM – Inner membrane. OM – 




Studies have shown that OMFs and transporters can interact directly (Symmons, 
Bokma et al. 2009, Tikhonova, Yamada et al. 2011). However, an “open” mutant of 
TolC in which mutations in the aperture rendered the protein unable to close showed 
significantly lower affinity for the AcrB transporter than the wild-type TolC. 
(Tikhonova, Yamada et al. 2011) This suggests that opening of the channel leads to a 
destabilization of interactions between the transporter and OMF, ultimately resulting in 
disengagement of the channel and closing of the aperture. The interface between AcrB 
and TolC is proposed to form between β-hairpins extending from the TolC docking 
domain on the periplasmic side of AcrB and the periplasmic tip of TolC (Weeks, Bavro 
et al. 2014). This interface is considered limited, and while it could initiate opening of 
the channel, it is not sufficient to maintain interactions with the open OMF. 
Additionally, transporters from the ABC and MF superfamilies of transporters lack the 
same large periplasmic domains of RND-type transporters, indicating that the interface 
between the transporter and the OMF is not required for a functional efflux complex 
(Lu and Zgurskaya 2013). Opening and subsequent stabilization of the OMF is thought 
to be induced by the third and final component of Gram-negative tripartite complexes, 




I.4 – Roles of membrane fusion proteins in transport  
In Gram-negative bacteria, MDR complexes typically consist of three 
components forming a large transporter capable of spanning both the inner and outer 
membranes of Gram-negative cell envelopes. Efflux occurs most effectively by 
transporting substrate through the outer membrane and into the medium. The inner 
membrane transporter (IMF) is responsible for binding of substrate and utilization of 
energy, and spans the inner membrane. Most IMFs extend into both the cytoplasmic and 
periplasmic space. To link the transporter to the OMF, periplasmic adaptor proteins, or 
membrane fusion proteins (MFPs) exist in the periplasmic space and provide a 
functional linkage of the transporter and OMF. MFPs pose an important, though not 
fully understood role in the overall transport process (Zgurskaya, Yamada et al. 2009, 
Zgurskaya, Weeks et al. 2015). Investigation of MFPs will provide important 
information about the mechanism of export in multidrug efflux systems. 
MFPs are bacterial proteins known to associate with a wide diversity of 
transporters belonging to many protein families (Weeks, Nickels et al. 2015). A 
multitude of functions have been associated with MFPs, ranging from physical linkers 
between the inner and outer membrane components of the transporter, to actual binding 
of substrate in the case of some MFPs (Su, Yang et al. 2009, De Angelis, Lee et al. 
2010, Delmar, Su et al. 2013, Lu and Zgurskaya 2013). AcrA and MacA have also been 
shown to stimulate the activities of their associated transporters (Zgurskaya and Nikaido 
1999, Tikhonova, Devroy et al. 2007). MFPs function as a hexameric unit, and multiple 
MFPs from different families of transporters have been crystallized. Some MFPs such 
as CusB have been crystallized in complex with other transporter components, yielding 
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insight into how MFPs interact with their cognate transporters and OMFs (Akama, 
Kanemaki et al. 2004, Su, Yang et al. 2009, Yum, Xu et al. 2009, Greene, Hinchliffe et 
al. 2013, Du, Wang et al. 2014, Hinchliffe, Greene et al. 2014). The MFP is thought to 
have a resting state in complex with the transporter, upon response to stimuli, possibly 
binding of substrate, the MFP recruits the OMF to the complex. Binding of the OMF 
then triggers a conformational change in the MFP required for the stimulation of the 
cognate transporter. This dual role of the membrane fusion protein raises questions as to 
how the molecule interacts with and translates conformational energy to the rest of the 
complex. As a tripartite complex, all proteins work together to expel substrate into the 
extracellular space (Ge, Yamada et al. 2009, Modali and Zgurskaya 2011). While 
primary sequences among MFPs are not well conserved, their structures are generally 
conserved. MFPs are elongated molecules composed of four domains in a linear 
conformation that is proposed to extend from the inner membrane surface up through 




Figure I.3 – Diagram of typical MFP structure. 
A. Linear representation of domain arrangement in MFPs from N-terminus to C-
terminus. TMS / SP – Transmembrane segment / signal peptide. MP – Membrane 
proximal. BB – β-barrel. B. Crystal structure of the MFP MexA. (PDB ID: 2V4D) 
Domain organization is colored similarly in both primary sequence and in structure. 





The conserved 4-domain structure of MFPs begins with membrane proximal 
(MP) domain that lies near the inner membrane, containing both the N- and C-terminus 
of the MFP. Some MP domains contain a transmembrane segment that anchors the MFP 
to the inner membrane (Zgurskaya and Nikaido 1999, Zgurskaya, Weeks et al. 2015). 
Directly above the MP domain lies the β-barrel domain. This domain is comprised of a 
number of β sheets forming a tight barrel conformation. The lipoyl domain is above the 
β-barrel domain and the domain furthest from the membrane region of the MFP is the α-
helical hairpin domain. The α-helical hairpin is composed of two large antiparallel α-
helices connected by a short loop region. Each of these domains are connected via short 
unstructured regions which are thought to impart a large range of interdomain flexibility 
to the protein. This flexibility is believed to be important for functional interactions with 
both transporters and OMFs (Mikolosko, Bobyk et al. 2006).  
MFPs oligomerize and assemble a structure in which the α-helical hairpins 
interact and form a funnel that interacts with the OMF. The cognate transporter interacts 
with the MP, β-barrel, and possibly the lipoyl domain (Zgurskaya, Weeks et al. 2015). 
Variations in the domains are seen in MFPs corresponding to unique transporters such 
as EmrB of E. coli (Hinchliffe, Greene et al. 2014). Crystal structures of the MF 
transporter EmrB reveals little to no periplasmic extension, and in accord, the MFP 
EmrA lacks a MP domain (Hinchliffe, Greene et al. 2014). Additionally, the α-hairpin 
of EmrA is very long in order to extend through the periplasmic space and interact with 
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the OMF. Contrarily, the MFP BesA of the BesABC complex of Borrelia burgdorferi 
lacks an α-hairpin domain entirely (Figure I.4) (Greene, Hinchliffe et al. 2013).  
 
 
Figure I.4 – Comparison of some crystallized MFPs.  
Comparison of the domains of a representative subset of MFPs, highlighting the 
structural diversity of the protein family. Figures adopted from (Bavro, Marshall et al. 
2015) 
 
The interactions of MFPs with OMFs and transporters have not been fully 
revealed, and much debate exists about placement of the MFP on either component of 
the complex. MFPs have also been identified in Gram-positive bacteria, which poses an 
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intriguing question as to the role of a membrane fusion protein in an organism 
containing only a single membrane (Harley, Djordjevic et al. 2000). 
Some MFPs have been crystallized in complex with their cognate transporters, 
and components of the complex exist in a monomer ratio of 3 IMF : 6 MFP : 3 OMF 
(Symmons, Bokma et al. 2009, Su, Long et al. 2011, Du, Wang et al. 2014). When 
crystallized alone, MFPs repeatedly form dimer pairs, indicating the dimer is the 
functional unit for the MFP (Akama, Matsuura et al. 2004, Mikolosko, Bobyk et al. 
2006, Yum, Xu et al. 2009). The affinity for oligomerization and stability of dimers 
varies between MFPs, and some studies have shown that interaction with the 
periplasmic domain of the transporter stabilizes the MFP oligomer (Tikhonova, 
Dastidar et al. 2009). However, due to the flexibility of the interdomain linker regions 
of the protein, different monomers of the dimer unit are believed to have different 
conformations (Akama, Matsuura et al. 2004). In addition, when crystallized with the 
transporter, the individual MFPs make different contact interfaces with both the 
transporter as well as the OMF (Su, Long et al. 2011).  This suggests that one protomer 
may have a different role than the other when functioning together with the transporter. 
Possibly the strongest evidence for the inequivalence of MFP dimers comes from the 
Pseudomonas aeruginosa triclosan transporter TriABC-OpmH. This complex consists 
of two separate MFPs, TriA and TriB, that are both required for functionality of the 
complex (Mima, Joshi et al. 2007).  
Previous studies have converged on a three-step model of MFP-dependent 
transport. Firstly, the MFP and transporter are proposed to exist in complex, located to 
the inner membrane (Lu and Zgurskaya 2012). Upon response to stimuli, possibly 
 
19 
binding of drug, a conformational change in the MFP occurs that recruits the OMF to 
the MFP-transporter complex (Janganan, Bavro et al. 2013). The channel is then opened 
through a conformational change (Lobedanz, Bokma et al. 2007, Tikhonova, Dastidar et 
al. 2009, Zgurskaya, Weeks et al. 2015). After formation of the fully assembled 
transporter, the MFP then stimulates the activity of the transporter (Ge, Yamada et al. 
2009, Modali and Zgurskaya 2011) so that drug is expelled through the outer membrane 
channel and into the extracellular space. Interactions between the OMF and the rest of 
the complex are thought to be transient (Tikhonova, Dastidar et al. 2009), and upon 
dissociation of the OMF, the complex resets back to the resting state. 
It has become recently clear that MFPs play a very active role in the efflux 
process (Zgurskaya, Weeks et al. 2015). They are shown to be involved with substrate 
binding, recruitment of OMFs, and stimulation of transporters. Although their role is 
becoming less vague, the exact interactions of this required transporter component with 
the other complex proteins are unclear. Specifically, it is still not understood how the 
MFP accomplishes the two roles of OMF recruitment and transporter stimulation. It is 
possible that homomultimeric MFPs assume different roles for each protomer, but we 
have not yet had the tools to investigate the differences between these protomers. 
Through the investigation of unique MFP-containing complexes such as YknWXYZ 
and TriABC, the specific roles of the MFP can be elucidated, providing insight into the 





I.5 – TriABC contains two unique membrane fusion proteins 
TriABC is an RND-type transporter found in P. aeruginosa. TriABC was 
identified by Mima et. al 2007 by subjecting an efflux-deficient P. aeruginosa strain 
PAO509 to increasing triclosan concentrations. The resulting triclosan-resistant strain 
PAO509.5 contained an overexpressed protein complex, TriABC (Mima, Joshi et al. 
2007). TriABC functions with the outer membrane pump OpmH in P. aeruginosa. 
TriABC consists of the inner membrane RND transporter TriC, and the two MFPs TriA 
and TriB. The complex resembles a standard RND-type efflux complex, except that it 
contains two MFPs present in the same operon. Both membrane fusion proteins are 
required for function and are quite distinct (Mima, Joshi et al. 2007). TriA only has 36% 
identity and 51% similarity when compared to TriB. To envision how this dual-MFP 
system could function, Mima et al. suggested that TriA and TriB could oligomerize in a 
heteromultimer, in which the MFPs could exist in a ratio of 3:3:3:3 
TriC:TriA:TriB:OpmH (Mima, Joshi et al. 2007). This fits with the model where the 
MFP exists as a stable dimer that then further trimerizes to form the fully functional 
MFP unit. While other efflux complexes are able to go through the efflux process 
utilizing a single MFP, TriABC requires both TriA and TriB individually. The inequal 
MFP dimer observed in previously mentioned crystal structures has led to speculation 
that the different conformations of MFPs observed retain unique functional aspects as 
well. However, it has been difficult to investigate this speculation, as most studies have 
focused on homomultimeric MFPs (Greene, Hinchliffe et al. 2013, Zgurskaya, Weeks et 
al. 2015). The heteromultimeric nature of TriABC provides a useful system in which to 
study the differential roles of MFPs. Investigation of TriABC can determine if the 
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individual protomers of the functional dimeric unit actually do assume different roles in 
the transport process.  
 
I.6 – YknWXYZ is a unique Gram-positive MFP-dependent transporter 
YknWXYZ is an ABC-type transporter from Bacillus subtilis that provides 
resistance to an endogenously-produced peptide, SdpC (Butcher and Helmann 2006). 
The unprocessed peptide, sporulation delaying protein (SDP) is produced by B. subtliis 
under starvation conditions and causes lysis of surrounding cells by collapse of proton-
motive force. Lysis then frees nutrients to be absorbed by other cells in order to delay 
the costly process of sporulation (Lamsa, Liu et al. 2012, Yamada, Tikhonova et al. 
2012). YknWXYZ is upregulated by the σ-W regulon, which is activated in response to 
antibiotic exposure in growing B. subtilis cells (Butcher and Helmann 2006). The first 
protein in the operon, YknW, is highly conserved among Bacillus species, but absent 
from the genomes of other bacteria (Yamada, Tikhonova et al. 2012). It contains a 
conserved Yip1 domain known to be involved with interaction of Rab GTPases in in 
eukaryotes, and in vesicular transport in yeasts (Yamada, Tikhonova et al. 2012).  
The three other genes, YknXYZ, encode a membrane fusion protein, ATPase, 
and membrane permease respectively. The MFP YknX is predicted to contain a single 
N-terminal transmembrane segment, followed by the typical MFP structure. YknY and 
YknZ express components that are thought to assemble to form a complete ATPase and 
permease (Butcher and Helmann 2006). Other ABC-type transporters such as MacAB-
TolC of E. coli contain the ATPase and permease components expressed as a single 
polypeptide (Kobayashi, Nishino et al. 2003), but YknWXYZ expresses these proteins 
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separately (Yamada, Tikhonova et al. 2012). The ATPase portion of YknY incorporates 
the three conserved motifs found in ABC-type transporters, the Walker A, Walker B, 
and ABC signature motif, while YknZ forms a permease thought to cross the membrane 
of B. subtilis (Butcher and Helmann 2006, Yamada, Tikhonova et al. 2012).  
When overproduced from a plasmid, YknWXYZ was found to protect cells from 
both endogenous and exogenously produced SdpC. With the exception of YknW, the 
loss of any complex component resulted in a loss of functionality. However, YknW 
alone only provides a partial functionality to SdpC (Yamada, Tikhonova et al. 2012). 
The requirement of an MFP in a Gram-positive organism implies certain functions of 
the MFP that would be conserved between Gram-positive and Gram-negative 
organisms.  This indicates that MFPs have a very active role in the transport process for 
them to be conserved in an organism only requiring transport across a single lipid 
bilayer, but their specific function in the context of a Gram-positive environment 
remains unknown. 
 
I.7 – Specific aims and goals of this dissertation 
Both TriABC and YknWXYZ are unique efflux systems that require 
nonstandard composition for function. They are also very different from one another, in 
that they are expressed in different native organisms and come from different efflux 
families. We currently do not know how MFPs interact with their complex components 
and how these interactions beget the dual role of OMF recruitment and transporter 
stimulation. Understanding how unique MFPs interact and work with their cognate 
transporters will give insight into the mechanism of MFP-mediated efflux. This 
 
23 
understanding will serve as a basis for updating the model of transport in both RND- 
and ABC-type transporters, and in the process shed light on the multiple roles of MFPs. 
In this dissertation, the goal is to characterize the unique MFPs TriA and TriB, and 
determine how two different MFPs interact with their cognate transporter and OMF. We 
will accomplish this using a combination of deletion and point mutations, combined 
with co-purification and functional studies. Understanding of the TriABC transporter 
serves to demonstrate how two unique MFPs interact differently with complex 
components, demonstrating the dual role of MFPs. 
We also seek to characterize the Gram-positive MFP YknX, and investigate 
protein-protein interaction of the complex, as well as the conservation of known MFP 
functions in a Gram-positive system. We will accomplish this through the construction 
of fusion as well as chimeric proteins, combined with ATPase assays that allow us to 
quantify the activity of the complex. This understanding will demonstrate the function 
of the MFP in the absence of an OMF. The completion of these aims will provide an 
update to the model of MFP-mediated efflux transporters in bacteria, and lay the 
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 The amber codon was introduced to AcrA position R225 using a QuikChange 
Lightning site-directed mutagenesis kit (Agilent) using p151AcrAB as a template with 
AcrA*fwd and AcrA*rev primers (Ma, Cook et al. 1993) The resulting plasmid was 
sequenced at Oklahoma Medical Research Foundation to confirm the substitutions. 
 Genes encoding TriAHis, TriBHis, and TriABHis were cloned into 
pBAD/Myc-His C using PCR product from PAO1 genomic DNA as a template in 
combination with TriA NcoI FWD, TriB NcoI FWD, TriA-His XhoI REV and TriB-His 
XhoI REV primers where appropriate. PCR produce and vector were cut with NcoI and 
XhoI before ligation using T4 DNA ligase (New England Biolabs). A C-terminal tag 
composed of 6 histidine residues was introduced prior to the native stop codon of the 
triA or triB genes during PCR. Primers used for PCR are listed in appendix A. 
Additionally a construct encoding a TriA-TriB fusion protein (TriAxB) was also 
constructed in which the native stop codon of triA was removed, a flexible five amino 
acid linker region was added, and the N-terminal signal peptide of triB was removed 
including the proposed modified cysteine residue using the primers TriAxB XbaI 
Fusion FWD and TriAxB XbaI Fusion REV. This pBAD-AxB plasmid was constructed 
from the pBAD-AB plasmid using a QuikChange Lightning site-directed mutagenesis 
kit (Agilent). Primers used are listed in Appendix A. For ease of screening potential 
positives, an XbaI site was engineered into the linker region.  
To construct pBSP-AxBC, pBAD-AxB was digested with AgeI/Bpu10I, which 
created a fragment of DNA encoding the C-terminus of TriA, TriAxB fusion segment, 
and the N-terminus of TriB. This fragment was then cloned into pPS1824 digested with 
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AgeI/Bpu10I, resulting in pBSP-AxBC. Positive clones were confirmed by XbaI 
digestion and sequencing at Oklahoma Medical Research Foundation. Additionally, 
genes encoding TriABCStrep and TriAxBCStrep were cloned into pBAD33 by using either 
pPS1824 or pBSP-AxBC as template for PCR with SacI TriA FWD and TriC-Strep 
HindIII REV primers for amplification. PCR products, as well as pBAD33, were 
digested with SacI-HF and HindIII-HF. Additionally, TriCHis was cloned into 
pBAD/Myc-His C by first amplifying the triC gene with a primer TriC-His HindIII 
REV encoding a 6His-tag. The PCR product was then digested with PciI and HindIII, 
while pBAD/Myc-His was digested with NcoI and HindIII. Ligation reactions were 
performed per the manufacturer’s protocol (New England Biolabs).  
Point mutations were introduced using a QuikChange Lightning Site-Directed 
Mutagenesis kit and primers designed according to manufacturer’s guidelines (Agilent 
Technologies). Primers are listed in appendix A. Plasmids were purified using a Qiagen 
Mini-Prep Kit and the coding sequences of TriABC were sequenced at the Oklahoma 
Medical Research Foundation Sequencing Facility to confirm the introduction of the 
desired substitutions. 
C-terminal deletions of TriA and TriB were constructed in pBAD33-ABC using 
PCR. Briefly, forward and reverse primers were designed to amplify in the forward 
direction from stop codon, and in the reverse direction from the beginning of the deleted 
area, creating a PCR product consisting of the entire pBAD33-TriABC plasmid, 
excepting the area to be deleted. A26rev and A47rev primers were designed to create 
PCR products missing the indicated number of 3-letter codons, resulting in deletions of 
the indicated number of amino acids from the final protein product. Actermfwd was 
 
30 
designed to amplify the region before the stop codon of TriA, replacing the native 
overlapping stop / start codon with an NdeI site, which would preserve the overlapping 
stop / start codon with an isoleucine residue inserted at the end of TriA. NdeI-digested 
PCR products and pBAD33 were ligated using T4 DNA ligase according to the 
manufacturers protocol (New England Biolabs). TriB deletions were constructed in the 
same way, but using primers B9rev, B30rev, and Bctermfwd. Primer sequences are 
listed in appendix A. TriAxBC TriA-deletion mutants were made using the same 
method, but instead of an NdeI site, an SpeI site was utilized, which encodes for serine 
and threonine before the AxB linker. Specific primers were Ax26rev, Ax47rev, and 
Axctermfwd. TriAxBC TriB mutations were made using the same primers as TriABC 
TriB-mutations. 
pBSP-TriAR130DBC, pBSP-TriBR118DBC, pBSP-TriA∆CCBC, and pBSP-
TriB∆CCBC along with their equivalent TriAxB variants were created by amplifying the 
entire coding gene from the corresponding pBAD33-based plasmid using the primers 
TriA-SacIfwd and TriC-HindIIIrev. PCR product and pBSPII(-SK) were digested using 
SacI and HindIII before ligation according to the manufacturer’s protocol. 
 To construct pET21d(+) YknYLZ, yknY and yknZ were amplified separately 
using PCR with B. subtilis 168 genomic DNA as a template. The primers yknY-f and 
yknY-r were flanked by NcoI and XhoI sites, respectively, and the primers yknZ-f and 
yknZ-r were flanked by SalI and XhoI sites, respectively. The linking region, taken 
from pET-MacB was amplified using primers L-fwd and L-rev containing SalI and 
XhoI sites, respectively. DNA cut by either XhoI or SalI have an overhang of 5’-
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TCGAC-3’ and are compatible for ligation, but upon ligation will form a site incapable 
of being cut by XhoI or SalI. 
 
Strain construction 
E. coli JWW1, JWW2, and JWW3 strains were derived from ET103 (BW25113 
ΔompT::Kmr) (Tikhonova, Devroy et al. 2007). The kanamycin resistance marker was 
scarred out using pCP20 as described in (Datsenko and Wanner 2000) in order to create 
JWW1. JWW1 was then transduced with P1 phage carrying the ΔacrAB::Kmr allele 
from RAM1419 (Weeks, Celaya-Kolb et al. 2010) using standard laboratory procedures 
to produce JWW2. JWW2 was then transduced with P1 phage carrying the tolC::Tn10-
48 allele from RAM958 (Vakharia, German et al. 2001) to construct JWW3. LB broth 
and Terrific Broth (TB) (12 g of Bacto tryptone, 24 g of yeast extract, 4 ml of glycerol 
per 900 ml of water supplemented with 100 ml of 0.17 M KH2PO4, 0.72 M K2HPO4) 
were used for bacterial growth and supplemented with ampicillin (100 µg ml-1), 
chloramphenicol (12.5 µg ml-1), kanamycin (25 µg ml-1), carbenicillin (200 µg ml-1), 
tetracycline (10 µg ml-1), gentamicin (30 µg ml-1), or trimethoprim (45 µg ml-1) when 
necessary. All chemicals used were of Molecular Biology grade. 
P. aeruginosa strains JWW4, JWW5, JWW6, and JWW7 were created by first 
deleting the opmH gene from P. aeruginosa PAO509.5 (Mima, Joshi et al. 2007) by 
mating with E. coli SM10 containing pPS1283 (pEX18-AP-opmH-Gm) leading to 
JWW4. For mating, PAO509.5 and SM10 freshly transformed with pPS1283 were 
grown to OD600 ~0.2. Donor and recipient cells (2 x 10
8 cells) were collected and mixed 
in 50 µl of LB and plated on LB agar plates overnight at 37°C. The next day, mated 
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cells were collected and resuspended in 5 ml of 10 mM MgSO4. 100 µl of resuspended 
mated cells were plated on Vogel-Bonner (VB) minimal medium agar plates (0.2 g of 
magnesium sulfate, 2 g of citric acid, 10 g of anhydrous dibasic potassium phosphate, 
3.5 g of sodium ammonium phosphate, 15 g of agar per liter (Vogel and Bonner 1956) 
supplemented with 30 µg ml-1 gentamicin and 5% sucrose for 24 – 48 hr at 37°C (de 
Lorenzo and Timmis 1994). Colonies were screened for carbenicillin sensitivity on LB 
agar containing carbenicillin (200 µg ml-1) to confirm proper integration of the pPS1283 
plasmid and removal of the wild type opmH gene. Gentamicin resistant, carbenicillin 
sensitive colonies were analyzed by PCR of genomic DNA to confirm the deletion of 
opmH. Insertion of genes encoding 6x histidine-tagged OpmHHis, TolCHis, or MCS onto 
the chromosome of JWW4 was performed by transforming PTJ1 carrying either 
OpmHHis, TolCHis, or an empty MCS by previously described protocols (Damron, 
McKenney et al. 2013). 
 
Photocrosslinking of AcrAB 
pUC151 plasmid containing AcrAB and variants were transformed into JWW2 
cells either with or without pEVOL-AzF or pEVOL-BzF and grown on LB agar 
containing ampicillin (100 µg ml-1) and chloramphenicol (12.5 µg ml-1) where 
appropriate. Colonies were inoculated from plates into LB broth containing ampicillin 
(100 µg ml-1) and chloramphenicol (12.5 µg ml-1) where appropriate and allowed to 
grow overnight, and the next day, a fresh culture was inoculated at a 1/50 dilution and 
grown for 5 hours in either Luria-Bertani (LB) broth (10 g of Bacto tryptone, 5 g of 
yeast extract, and 5 g of NaCl per liter, pH 7.0), media or 2x YT (16 g tryptone, 10 g of 
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yeast extract, and 5 g of NaCl per liter, pH 7.0). p-azido-L-phenylalanine (AzF) 
(BACHEM) or p-benzoyl-L-phenylalanine (BzF) (BACHEM) were added where 
appropriate to a final concentration of 1 mM. Cells were collected via centrifugation at 
3,220 g for 20 minutes, washed in 10 mM Tris-Cl, pH 7.5, and protected from UV 
exposure before any following experiments.  
Cells containing AcrA* were resuspended in buffer containing 20 mM Tris-HCl 
(pH 7.5) and 100 mM NaCl. Resuspended cells were then placed in a 24-well sterile 
cell culture plate (Falcon) and the plate packed in ice. With the lid removed, cells were 
exposed to UV light for 0-60 minutes using a handheld lamp set to 365 nm. After 
exposure, cells were collected via centrifugation at 3,220 x g for 20 minutes and either 
frozen or lysed for membrane isolation. Lysis was performed by resuspending AcrA*-
containing cells in buffer containing 1 mL of 20 mM Tris-HCl, 500 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), and 100 μg / mL lysozyme. Resuspended cells 
were incubated on ice for one hour, and broken by sonication. Unbroken cells were then 
removed by centrifugation at 3,220 x g for 20 minutes, and membrane fractions were 
collected by centrifugation of the supernatant at 100,000 x g for 1 hour. 
 
Purification of AcrA from E. coli 
Cells containing AcrA were grown and lysed as previously described. 
Membranes were resuspended in 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 5% Triton 
X-100, and 1 mM phenylmethanesulfonylfluoride (PMSF), and allowed to solubilize on 
a rotator (Thermo) overnight at 4° Celsius. The next day, the solubilization suspension 
was centrifuged at 100,000 x g for 1 hour to pellet insoluble material, and the 
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supernatant was loaded onto a 1 mL Ni-NTA column charged with Cu2+. The column 
was washed with a buffer containing 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 0.2% 
Triton X-100, 1 mM PMSF, and  5 mM imidazole. The column was washed using the 
same buffer containing increasing imidazole concentrations of 10 column volumes of 
20 mM imidazole, 10 column volumes of 50 mM imidazole, and then protein elution 
utilized 2x 1 column volume of 100 mM imidazole and 3x 1 column volume of 500 mM 
imidazole. 
 
Minimal inhibitory concentrations (MICs) 
Overnight cultures of P. aeruginosa or E.coli carrying indicated constructs were 
diluted 1 to 100 in LB broth supplemented with a selective marker grown at 37°C with 
shaking at 200 RPM for 5 hours.  MICs of antimicrobial agents were measured using 
the two-fold dilution technique in 96-well microtitre plates (Tikhonova, Wang et al. 
2002). At an optical density at 600 nm (OD600) of ~1.0, cells were inoculated at a 
density of 5x104 cells per ml in LB in the presence of two-fold increasing 
concentrations of antibiotics under investigation.  The cultures were incubated for 24 h, 
and the lowest concentration that completely inhibited bacterial growth was designated 
the MIC. When required, protein expression was induced by adding 1.0 mM IPTG, 
0.2% L-arabinose, 1% L-arabinose, or 1% xylose to cell cultures at OD600 of ~0.3-0.5, 




Purification of TriABC components from E. coli 
E. coli JWW2 competent cells were co-transformed with pBAD33-TriABC 
constructs and / or pBAD-TriC where appropriate, plated on LB agar supplemented 
with ampicillin (100 µg ml-1) and chloramphenicol (12.5 µg ml-1) where appropriate, 
and grown overnight at 37°C. Cells were then cultured in 5 ml LB containing ampicillin 
(100 µg ml-1) and chloramphenicol (12.5 µg ml-1) where appropriate overnight at 37°C 
with shaking, and sub-cultured 1/50 into 250 ml TB supplemented with ampicillin (100 
µg ml-1) and chloramphenicol (12.5 µg ml-1) where appropriate. Cultures were grown at 
37°C with shaking for 3 hours before induction with 0.2% L-arabinose for 5 hours. 
Membrane fractions were collected by lysing cells in 35 mL of 20 mM Tris-HCl pH 
8.0, 500 mM NaCl, 1 mM EDTA, and 100 μg / mL lysozyme. Resuspended cells were 
incubated on ice for one hour, and broken by sonication. Unbroken cells were then 
removed by centrifugation at 3,220 x g for 20 minutes, and membrane fractions were 
collected by centrifugation of the supernatant at 100,000 x g for 1 hour. Membrane 
pellets were then re-suspended in 3 ml solubilization buffer (20 mM Tris-HCl pH 7.5, 
500 mM NaCl, 1 mM PMSF, 5 mM imidazole, 5% Triton X-100) and incubated 
overnight on a rotator. Insoluble fractions were collected via centrifugation at 100,000 x 
g for 1 hour, and the solubilized membrane fractions were loaded onto a 100 μl Cu2+ 
charged HisBind Resin (EMD Millipore) column equilibrated with Buffer A (50 mM 
Tris-HCl pH 7.5, 500 mM NaCl, 1 mM PMSF, 5 mM imidazole) supplemented with 
0.2% Triton X-100. Flow-through was re-applied to the column to ensure complete 
binding, and the column subsequently washed with 10 column volumes of Buffer A 
containing 5 mM imidazole followed by 20 column volumes of Buffer A containing 40 
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mM imidazole. Protein was eluted using 3.5 column volumes of Buffer A containing 
400 mM imidazole. Fractions were then analyzed for protein amount using sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and combined for 
normalization and immunoblotting.  
 
Purification of OpmHHis from P. aeruginosa 
To purify OpmHHis, P. aeruginosa JWW6 cells were grown overnight in LB, 
cells were subcultured 1:100 into fresh LB and incubated until OD600 ~0.3. At OD600 
~0.3, cultures were induced with 1% L-arabinose for an additional 4.5 hours. Cells were 
collected by centrifugation at 3220 x g for 20 min. Membranes were prepared as 
described above. Membranes were resuspended in Buffer A (50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1 mM PMSF, 5 mM imidazole pH 7.5) supplemented with 2% n-
Dodecyl β-D-Maltoside (DDM) overnight at 4°C. Solubilized membranes were 
centrifuged for 1 hour at 100,000 x g. Soluble proteins were applied to a 100 µl Cu2+-
charged His-Bind Resin column equilibrated with Buffer A containing 5 mM imidazole 
and 0.03% DDM. Columns were washed with 10 column volumes of Buffer A 
containing 5 mM imidazole and 0.03% DDM, followed by 20 column volumes of 
Buffer A containing 75 mM imidazole and 0.03% DDM. OpmHHis was eluted in 4 
column volumes of Buffer A containing 400 mM imidazole and 0.03% DDM. Fractions 
were then analyzed for protein concentration using SDS-PAGE as described below, and 
peak fractions were combined for immunoblotting.  
 
Purification of YknYLZ 
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pET-21d(+) plasmid containing YknYLZ was transformed into E. coli C43 cells 
and plated on LB agar plates containing ampicillin (100 µg ml-1) and incubated at 37° 
Celsius overnight. After incubation, cells were inoculated from plates into LB broth 
containing ampicillin (100 µg ml-1) and grown overnight at 37°C with shaking. The 
next day, a fresh culture was inoculated at a 1/100 dilution and grown for 2-3 hours 
until O.D. 600 reached 0.3-0.5. Protein expression was induced using a final 
concentration of 1 mM IPTG for 3-4 hours. Cells were then collected via centrifugation 
at 3,220 x g for 20 minutes, washed with 10 mM Tris-HCl (pH 8.0), and either frozen 
for later use or resuspended in lysis buffer containing 20 mM Tris-HCl (pH 8.0), 5 mM 
EDTA, 1 mM PMSF, and 100 μg / mL lysozyme. Resuspended cells were incubated on 
ice for one hour, and then broken by sonication. Unbroken cells were then removed by 
centrifugation at 3,220 x g for 20 minutes, and membrane fractions were collected by 
centrifugation at 100,000 x g for 1 hour. Membranes were resuspended in 40 mM Tris-
HCl (pH 8.0), 2 mM PMSF, and solubilized by addition of lysophosphatidylglycerol 
(LPG) to a final concentration of 20 mg/mL and incubation on a rotator at 4° Celsius 
overnight. The next day, the solubilization mixture was centrifuged at 100,000 x g for 1 
hour to pellet insoluble material, and the supernatant was loaded onto a 1 mL Ni-NTA 
column charged with Ni2+. Protein was washed and eluted with a buffer containing 20 
mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM PMSF, and 1 mg/mL LPG and increasing 
imidazole concentrations of 5 mM, 30 mM, 50 mM, 100 mM, 250 mM and 500 mM.  
For detergent exchange, protein was purified in the same manner, except 
solubilized in 5% Triton X-100 rather than LPG. After elution, purified protein was 
dialyzed twice over in 1 L of 20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM PMSF 
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and 1 mg/mL LPG. Dialyzed fractions were then re-loaded onto the Ni-NTA column, 
and detergents were exchanged by running 20 column volumes of binding buffer 
containing 2 mM LPG, then eluting the protein and dialyzing as previously done in 
Triton X-100. To quantify, protein was then run on an SDS-PAGE gel using known 
BSA amounts as a standard. Amount of protein was quantified using ImageQuant, and 
protein concentrations were normalized to 1 mg/mL. 
 
Purification of proteins from B. subtilis 
Transformed B. subtilis HB6127 cells were scraped from solid media and 
inoculated into 5 mL of LB and grown overnight at 37° C with shaking. Cells were then 
re-inoculated into 20 mL of LB, grown for 2-3 hours, and then re-inoculated into 2 liters 
of LB and grown until the OD600 reached 0.4-0.5. Protein production was induced via 
addition of L-xylose to a final concentration of 0.5% for 3 hours. Cells were collected 
via centrifugation at 3,220 x g for 20 minutes and washed with 20 mM Tris-HCl (pH 
8.0). Cells were then resuspended in lysis buffer containing 50 mM Tris-HCl (pH 8.0), 
5 mM MgCl2, 1 mM PMSF, 50 mM NaCl and 0.05 mg/mL DNAse I for 1 hour, and 
then passed through a French Press at 18,000 psi. Unbroken cells were collected by 
centrifugation at 3,220 x g for 20 minutes, and membrane fractions were collected via 
centrifugation at 100,000 x g for 1 hour. Membranes were resuspended in 10 mL of 2x 
binding buffer (100 mM Tris-HCl pH 8.0, 10 mM MgCl2, 2 mM PMSF, and 100 mM 
NaCl) and then membranes were solubilized by addition of 10 mL of 2% DDM to a 
final concentration of 1% and incubation with rotation overnight at 4° C. Insoluble 
fractions were pelleted via centrifugation at 100,000 x g for 1 hour, and the soluble 
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portion was loaded onto a 1 mL Ni-NTA column charged with Ni2+ and equilibrated 
with 1x binding buffer (50 mM Tris-HCl pH 8.0, 5 mM MgCl2, 1 mM PMSF, and 50 
mM NaCl). The column was washed using imidazole concentrations of 5, 15, and 50 
mM, and then proteins were eluted in 100 mM and 500 mM imidazole steps. 
 
Transformation of B. subtilis 
B. subtilis HB6127 cells were plated onto solid media and incubated overnight 
at 37° C. The next morning, colonies were scraped and inoculated into 5 mL of SpI 
medium (1.4% K2HPO4, 0.6% KH2PO4, 0.1% sodium citrate, 0.002% MgSO4 – 7H2O, 
0.2% ammonium sulfate) + (0.002% casamino acids, 0.1% yeast extract, 50 μg/mL L-
tryptophan, and 0.5% glucose) and incubated at 37° Celsius for 4 hours. The 5-mL 
mixture was then re-inoculated into 50 mL of SpII medium (1.4% K2HPO4, 0.6% 
KH2PO4, 0.1% sodium citrate, 0.002% MgSO4 – 7H2O, 0.2% ammonium sulfate) + 
(0.02% yeast extract, 5 mM MgCl2, 50 μg/mL L-tryptophan, and 0.5% glucose) and 
incubated for 90 minutes at 37° Celsius. Cells were then collected via centrifugation and 
concentrated 20-fold by resuspension in SpII. 250 μL of concentrated cells were then 
mixed with 5 μL of plasmid DNA and incubated on ice for 30 minutes, then mixed with 
1 mL of LB broth. This mixture was then allowed to grow for 1 hour at 37°C with 
shaking, and plated on selective media. 
 
Antibody production 
Anti-TriAHis, anti-TriBHis, and anti-TriCHis antibodies were produced in rabbits 
by Covance. Briefly, proteins were purified from E. coli as described above. 
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Concentrations were determined and 250 µg of protein was used for initial 
immunization. Rabbits were boosted with 125 µg of protein at 21 day intervals for 3 
boosters. Production bleeds were collected 10 days post boosters with a final collection 
after 77 days. Rabbits were euthanized antibody post collection. 
 
SDS-PAGE and Western blotting 
SDS-PAGE was performed according to standard protocols. After SDS-PAGE, 
immunoblots were performed by electro-transfer of proteins onto a polyvinylidene 
fluoride (PVDF) membrane via immersion in transfer buffer (25 mM Tris-Cl, 
unadjusted pH, 192 mM glycine, 20% v/v methanol) at 70 V for one hour. After 
transfer, membranes were blocked in 10% dry milk solution for at least one hour. 
Primary antibodies were used at a dilution of 1:30,000 and incubated with membranes 
for at least three hours. Anti-rabbit and anti-mouse IgG secondary antibodies conjugated 
to alkaline phosphatase (Sigma) were also used where appropriate at a 1:30,000 dilution 
for an incubation period of at least one hour. Color development solution was prepared 
by mixing 1% 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and 1.5% nitro blue 
tetrazolium (NBT) to a final concentration of 0.02% BCIP and 0.03% NBT in AP buffer 
(100 mM Tris-Cl, pH 9.5, 100 mM NaCl, 5 mM MgCl2). Membranes were developed 
by three subsequent washes in tris-buffered saline (TBST) solution (50 mM Tris-Cl, pH 
7.6, 150 mM NaCl, 0.05% Tween 20) and then incubation in color development 





ATP hydrolysis by YknYLZ, MacB, YknY, and YknYZ was measured to 
determine the effect of YknX on the ATPase activity of the transporter. Generally, a 20 
μL reaction mixture containing 0.5 μg of protein, 20 mM HEPES-KOH (pH 7.0), 2 mM 
MgCl2, 50 mM KCl, 40 mg/mL lysophosphatidyl glycerol (LPG), and 1 mM Mg-ATP 
was incubated at 37° Celsius. ATP was prepared by mixing 32-P γ-phosphate ATP 
(3000 Ci mmol-1, Amersham) with 1 mM unlabeled Mg-ATP and added to a final 
reaction concentration of 1 mM. At designated time points, a 1 μL aliquot of the 
reaction was removed and added to 10 μL of stop buffer containing 50 mM Tris-HCl 
(pH 8.0), 20 mM EDTA (pH 8.0), 0.5% SDS, 200 mM NaCl, and 0.5 mg/mL proteinase 
K. The stopped reaction was then incubated at 55° Celsius for at least 20 minutes to 
completely denature ATP-hydrolyzing proteins. Afterwards, 1 μL of the stopped 
mixture was spotted on PEI-F cellulose plates, and reaction components were separated 
utilizing thin-layer chromatography (TLC). The mobile phase was composed 10% 
formic acid and 0.5 mM LiCl. Amounts of free Pi were quantified using a Storm 
Phosphoimager and ImageQuant software (Molecular Dynamics). ATPase rates were 
calculated using pre-established protein concentration values in combination with 
reaction times and ATP concentration.  
 
Protein Concentration Determination 
Protein concentrations were determined using the Bradford Protein Assay (Bio-
Rad) with varying amounts of bovine serum albumin (BSA) as a protein standard. To 
determine the concentration of proteins solubilized in detergent solution, protein 
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samples and BSA were together separated on SDS-PAGE gels and stained with 
Coomassie Brilliant Blue (CBB). Gels were then scanned and protein band intensities 
quantified using either ImageQuant software (Molecular Dynamics) or ImageJ (NIH). 
Protein concentrations were then determined using intensities from known BSA 






Chapter 1.  Interactions between TriC and the MFPs TriA and TriB 
1.1 Abstract 
 MFPs function in tandem with an inner membrane transporter and an outer 
membrane factor. In Gram-negative bacteria, the MFP is proposed to provide a link 
between the two membrane-bound components of the transporter, and facilitate 
conformational changes in each component that are required for the efflux process. This 
study focuses on the paired-MFP transporter TriABC, in which the two MFPs TriA and 
TriB function with the RND-type transporter TriC in order to provide P. aeruginosa 
resistance against the antimicrobial compound triclosan. Through a mixture of co-
purification and functional studies, I establish that TriA and TriB function as a 
heterodimer in a 1:1 ratio and that the fused polypeptide TriAxB is functional. I also 
found that deletions in the membrane proximal domain of TriA and TriB severely affect 
their ability to interact with TriC, and that analogous mutations in TriA and TriB affect 
each protein differently. Additionally, point mutations in the MP domain of each protein 
affect complex function and assembly as observed through MIC measurements and co-
purification. Results show that TriA and TriB are not dependent on one another for 
interaction with TriC, and that their function and binding sites are unique, which 
suggests that TriA and TriB serve different roles in the transport process. This result 
implies that homomultimeric transporters also assume a dual role in transport, wherein 
each protomer of the dimer serves a distinct purpose. Additionally, I investigated using 
unnatural amino acids to photocrosslink membrane-bound transporter components using 
the well-studied RND transporter AcrAB as a model. I establish that unnatural amino 




MFPs are known to stimulate their cognate transporters (Zgurskaya and Nikaido 
1999, Tikhonova, Devroy et al. 2007), and a number of experiments have been 
performed to map the MFP-transporter interface (Tikhonova, Devroy et al. 2007, 
Weeks, Celaya-Kolb et al. 2010, Su, Long et al. 2011, Xu, Lee et al. 2011, Weeks, 
Bavro et al. 2014). These experiments focus mostly on the MP domain of MFPs, which 
is known to primarily interact with the transporter, and contains both the N- and C-
terminus of the protein (Zgurskaya and Nikaido 1999, Mikolosko, Bobyk et al. 2006). 
In RND transporters, the stoichiometry of the MFP:transporter complex is 6:3, resulting 
in two MFPs contacting each subunit of the transporter. Thusly, RND-associated MFPs 
are able to bind the transporter in different positions. In the only crystallized MFP-
transporter complex to date (Su, Long et al. 2011), the MFP CusA contacts the 
transporter CusB through two different interfaces. Additionally, the monomers forming 
the dimeric unit of the MFP retain two distinct conformations.  Consistent with this 
result, when the MFP MexA is crystallized, the dimer unit shows two separate 
conformations independent of the presence of a transporter (Akama, Kanemaki et al. 
2004). This indicates that MFPs may serve a dual role, and that the individual 
conformations held may serve a distinct functional purpose in transporters containing a 
single MFP.  
 The TriABC-OpmH efflux complex was identified in P. aeruginosa (Mima, 
Joshi et al. 2007). In this study, it was shown that overexpression of triABC as a result 
of a promoter-up mutation increased the resistance of P. aeruginosa cells to the 
antimicrobial compound triclosan. Triclosan is a commonly used biocide, appearing in 
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many hand soaps and other household items. TriABC is unique among MFP-dependent 
transporters due to the requirement of TriA and TriB, which have both been identified 
as MFPs, and are each required for complex function. Paired MFPs present the most 
natural evidence that the functional unit of MFPs is a dimer, and could provide a good 
model for studying how separate MFPs interact with their cognate transporter.  
To characterize the interactions between MFPs and transporters, we first focused 
on the P. aeruginosa transporter TriABC. TriABC is known to have two required 
MFPs, TriA and TriB that together form a functional efflux complex with TriC. To 
study how TriA and TriB interact differently with TriC, we made truncated versions of 
the MFPs as well as site-specific mutations in conserved residues. Making changes in 
TriA and TriB separately allows validation of a model in which each MFP of a dimeric 
unit serves a specific role and interacts with transporter components in a unique way. 
We then attempted to use a new method to determine the positions of of the MFP on the 
transporter by crosslinking site-specific residues of a typical MFP and cognate 
transporter. For this purpose, we used the best-characterized MFP-dependent transporter 
complex to date, AcrAB (Pos 2009). While crosslinking techniques such as cysteine-
cysteine and amine-based crosslinking have been utilized with membrane proteins 
previously (Elkins and Nikaido 2002, Symmons, Bokma et al. 2009, Yamada, 
Tikhonova et al. 2012), a relatively new technique of photocrosslinking (Chin, Santoro 
et al. 2002, Young, Ahmad et al. 2010) has not yet been tested in the realm of 
membrane-bound transporters. This approach would validate a new method for 
mapping site-specific interactions between MFPs and transporters, expanding the 




Figure 1.1 – Model of TriABC interactions. 
 
A. Top-down view of the complex. Individual protomers are distinctly colored. B. 
Bottom-up view of the complex. C. Side view of the complex. D. Interactions between a 
single protomers of TriA, TriB, and TriC. TriA is colored in green, TriB is colored in 
cyan, and TriC is colored in orange. Residues selected for point mutations in TriA and 





1.3.1 – TriABC-OpmH is a functional triclosan efflux complex in P. aeruginosa 
and E. coli 
Mima et. al. in 2007 isloated the P. aeruginosa strain PAO509.5, which 
reportedly overexpresses TriABC as a result of a promoter-up mutation. To confirm the 
increase in TriABC expression, we grew and isolated membrane fractions from various 
P. aeruginosa strains, including wild-type PAO1, the TriABC-deficient PAO1116, and 
the TriABC-overexpressing PAO509.5 (Table 1). Detection of TriA, TriB, and TriC 
using polyclonal antibodies specific for each protein showed that all three proteins are 
significantly upregulated in PAO509.5, likely leading to the increase in triclosan 
resistance observed in (Mima, Joshi et al. 2007). (Figure 1.2, panel A) 
Mima et. al also identified OpmH as the native OMF associated with the 
TriABC transporter. To investigate the interactions between TriABC and different 
OMFs, wild-type OpmH was deleted from the PAO1 chromosome, and PTJ1 plasmid 
recombination was used as described in (Damron, McKenney et al. 2013) to insert a 
gene at the att:Tn7 locus under an arabinose-inducible promoter. Empty vector, 
histidine-tagged OpmH, or histidine-tagged TolC was inserted create P. aeruginosa 
strains JWW5, JWW6, and JWW7, respectively (Table 1). JWW5, containing empty 
vector, was used as a negative control. TolC, a promiscuous OMF from E. coli was 
selected because of its similarity with OpmH as well as ability to function with multiple 
MFPs in E. coli (Zgurskaya, Krishnamoorthy et al. 2011). Cells were grown and 
membrane fractions collected as described in Methods, except when solubilizing 
membrane fractions, the inner membrane was solubilized by mild detergent extraction 
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of 0.2% Triton X-100. This allowed inner membrane proteins to be detected in the 
soluble fraction whereas the outer membrane and associated proteins remained in the 
insoluble pellet. Results indicate histidine-tagged OpmH is expressed, and is localized 
to the outer membrane. However, TolC is not expressed when chromosomally 
integrated onto the P. aeruginosa chromosome. (Figure 1.2, panel B) To purify OpmH, 
JWW5 cells were grown to mid-log phase and OpmH expression induced via 1% L-
arabinose for 4.5 hours. Cells were then lysed and membrane fractions collected as 
described in the Methods. Membrane fractions were solubilized in 2% DDM before 
isolating OpmH via a His-bind affinity chromatography column charged with Cu2+. 
Upon probing purified fractions with anti-poly His antibody to visualize OpmH, bands 
appeared confirming purified protein. Additionally, upon probing the same fractions 
with anti-TriA, anti-TriB and anti-TriC antibodies, bands corresponding to all three 
proteins were identified. (Figure 1.2, panel C) These results show that all three 
components of the TriABC complex interact with OpmH in P. aeruginosa, and that the 





Figure 1.2 – TriABC-OpmH is overexpressed in PAO509.5 and assembles as a 
complex localized to the membrane. 
A. Immunoblotting analysis of membrane fractions isolated from wild type PAO1 P. 
aeruginosa, the efflux-deficient PAO1116 strain, and the TriABC-overexpressing 
PAO509.5. Membranes were probed with anti-TriA, anti-TriB, or anti-TriC antibodies. 
B. OpmH localizes to the outer membrane of P. aeruginosa and co-purifies with TriABC. 
Immunoblotting of membrane fractions from P. aeruginosa strains containing either the 
integrated empty vector (JWW5), OpmHHis (JWW6), or TolCHis (JWW7). M – total 
membrane fraction. S – solubilized membrane fractions (inner membrane). P – insoluble 
membrane pellet (outer membrane). Membrane fractions were isolated from log phase 
cells after induction with 1% L-arabinose for 3 hours. Inner membrane proteins were 
solubilized by mild detergent (0.2% Triton X-100) extraction. Outer membrane proteins 
remained in the insoluble pellet. Membranes were probed with anti-poly His antibodies. 
C. Immunoblotting analysis of purified OpmHHis and co-purified proteins. Membranes 
were probed with anti-poly His, anti-TriA, anti-TriB, or anti-TriC. In this figure and 
others, unless indicated otherwise, membrane fractions were isolated from log phase 




Having confirmed that TriA, TriB, TriC, and OpmH together make a complex 
when overexpressed together (Figure 1.2), we set out to establish how TriA and TriB 
form a fully functional MFP unit. Current models of MFP-dependent transport place the 
MFPs in a side-to-side arrangement, forming a trimer of dimers that make connections 
to the IMF and OMF through the MP / β-barrel domains and the coiled-coil region, 
respectively (Zgurskaya, Weeks et al. 2015) (Figure I.3). Traditional MFPs are 
proposed to form homodimers, as a single MFP is used. Since TriA and TriB are 
distinct MFPs, they could either form homo- or heterodimers depending on 
arrangement. To determine the arrangement of paired-MFPs around the transporter, we 
created a fused construct, in which TriA and TriB are covalently linked as a single 
polypeptide by a flexible linker region. (Figure 1.3) This fusion protein, AxB, fixes the 
arrangement of MFPs in a heterodimer, allowing the ability to distinguish the functional 
unit of the MFP. This heterodimeric, fused MFP was expressed in P. aeruginosa 
through the plasmid pBSP-TriAxBC which was created through site-directed 
mutagenesis of pPS1824. TriAxBC was also expressed in E. coli by subcloning pBSP-







Figure 1.3 – Schematic representation of the TriAxB fusion protein.  
Illustration of the TriAxB fusion protein, in which the stop codon of TriA is removed 
and replaced with a flexible linker region, which is followed by TriB with the proposed 
signal peptide removed. Amino acid sequences of TriA and TriB show removed 
portions as underlined, and the linker region in TriAxB is underlined. 
 
MIC measurements were performed to determine substrate specificity of the 
pump. Only triclosan and SDS were found to be substrates of the TriABC complex. 
(Data not shown) To determine the functionality of the TriAxBC complex in P. 
aeruginosa, various plasmid constructs were transformed into the P. aeruginosa 
TriABC-deficient PAO1116. Additionally, the functionality of the complex was 
investigated in the E. coli strain JWW2 (BW25113 ΔompT-scar, ΔacrAB::Kmr). OpmH, 
the native outer membrane channel that functions with TriABC shares a high degree of 
similarity with the E. coli outer membrane channel TolC. If TriABC is functional in E. 
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coli, it would provide an ideal model system in which to study interactions between the 
well-known TolC and the comparatively little-studied TriABC.  
pBAD33-based plasmids were co-transformed into E. coli with the plasmid 
pBAD-TriC due to low expression of TriC from the full-length operon contained in 
pBAD33-TriABC (Data not shown). Additionally, to confirm OpmH as the functional 
OMF for TriABC, P. aeruginosa strains JWW5 (JWW4 attTn7::mini-Tn7T -Tpr -araC-
ParaBAD-MCS), JWW6 (JWW4 attTn7::mini-Tn7T-Tp
r -araC-ParaBAD-opmH), and 
JWW7 (JWW4 attTn7:: mini-Tn7T-Tpr -araC-ParaBAD-tolC) were tested, expressing 
TriABC from the chromosome. After cell growth and induction via 1% arabinose for 5 
hours, cells were plated in MIC experiments to test susceptibility to SDS and triclosan. 
Results show that the TriABC pump is functional in E. coli and P. aeruginosa, as is the 
fused TriAxBC construct. (Table 2) Thus, TriABC provides resistance against triclosan 
in E. coli and this organism can be used as a good host to study the TriABC complex. 
Additionally, the functionality of TriAxB indicates that TriA and TriB function side by 
side in a 1:1 stoichiometry. 
Because E. coli does not natively express OpmH, the native OMF to TriABC, it 
seems reasonable that the complex is assembling with the promiscuous E. coli OMF 
TolC, which is known to interact with a number of different RND-type efflux 
transporters. To determine if TriABC functions with TolC, MICs were tested again in 
the E. coli strain JWW3, which is TolC-deficient. Results show that JWW3 
susceptibility to SDS and triclosan is not rescued by TriABC or TriAxBC, indicating 
that indeed, TolC functions with the TriABC complex. (Data not shown) Finally, results 
in P. aeruginosa using strains with either chromosomally-integrated OpmH or TolC 
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show that deletion of OpmH from the chromosome eliminates complex functionality, as 
well as that TolC is unable to rescue the defect in efflux caused by OpmH absence 
(Table 2). This data establishes a baseline of the resistance level provided by TriABC, 
and the functionality of TriAxBC indicates that the two membrane fusion proteins 
function together as a dimer in a 1:1 molar ratio.  
 
 Strains Tri complex SDS  
(µg ml-1) 
Triclosan   
(µg ml-1)  
1 Pae JWW5 (attTn7::ParaBAD) - 39 0.25-0.5 
2 Pae JWW6 (attTn7::ParaBAD-
opmH) 
TriABC-OpmHHis >2500 >128 
3 Pae JWW7 (attTn7::ParaBAD-
tolC) 
TriABC-TolCHis  39 0.5 
     
4 Pae PAO1116 (pBSPII) - 156-312 16 
5 Pae PAO1116 (pPS1824) TriABC-OpmH >2500 128 
6 Pae PAO1116 (pBSP-AxBC) TriAxBC-OpmH >2500 128 
     
7 E. coli JWW2 (pBSPII) - 39 0.000125 
8 E. coli JWW2 (pPS1824) TriABC-TolC >2500 0.008 
9 E. coli JWW2 (pBSP-AxBC) TriAxBC-TolC >2500 0.008 
     
 * Pae- P. aeruginosa    
 
Table 2 – TriABC and TriAxBC are functional in P. aeruginosa and E. coli. 
Minimal inhibitory concentrations of SDS and triclosan are indicated for cells producing 




1.3.2 – Deletions in the MP domain of TriA and TriB drastically affect function 
Having confirmed the identity of the TriABC-OpmH complex, as well as the 
functionality of TriABC-TolC in E. coli, we began investigating the differences 
between the MFPs TriA and TriB. Sequence alignment of TriABC with various paired 
MFPs showed alignment of conserved residues in both the MP domain as well as the 
CC domain of TriA and TriB, indicating that they share the same architecture and 
general design as other MFPs (Figure 1.4) (Zgurskaya, Weeks et al. 2015). In order to 
determine if the MFPs TriA and TriB share the same role in the transport process, we 
used this sequence alignment to select site-specific substitutions of conserved residues 
in the MP domains of each TriA and TriB, as well as C-terminal truncations to 
determine if they would affect the function of the complex differently.  
It stands to reason that if TriA and TriB have different binding sites and 
interactions with TriC, then analogous mutations may affect the MFPs differently. 
Selections were made to mutate conserved glycine residues known to have an effect on 
interactions between the transporter and MFP in other transporters (Ge, Yamada et al. 
2009, Modali and Zgurskaya 2011). Using sequence alignment to find the 
corresponding residues in TriA and TriB, these conserved residues correspond to G350 
in TriA and G339 in TriB (Figure 1.4). These glycine residues were mutated to cysteine 
using site-directed mutagenesis for the possibility of utilizing functional crosslinkers in 
future experiments.  
To further characterize the role of the MP domain in MFP-transporter 
interactions, truncations were made, removing the C-terminal end of the MP domain up 
until a conserved proline-glycine motif, as well as past another conserved glycine in the 
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MP domain. Alterations in the MP domain could determine if TriA and TriB interact 
differently with the transporter. If disruptions between the MP domain and the 
transporter affect one protein, but not the other, it would stand to reason that 
interactions between MFPs and transporters can occur through different domains. Thus, 
the MFPs would likely have different functions in the fully assembled complex. After 
removal of the proposed signal peptide, TriA is longer than TriB by 17 residues (Figure 
1.4), and thusly when making deletions based on sequence alignment, would have a 
larger truncation than TriB. In TriA, deletions of both 26 and 47 amino acids were 
made, while in TriB, deletions of 9 and 30 residues were made. The rationale behind 
making both a small and a large deletion was to provide a range of truncations that may 
affect complex function in an intermediate manner. Deletions were constructed by PCR 
as described in Methods. Deletion mutants were created in plasmids carrying TriABC 






Figure 1.4 - Sequence alignment and deletions of TriA and TriB. 
Primary sequence alignment of the MFPs TriA, TriB, MexA, and AcrA. Deletions made 
in the MP domain of TriA and TriB are marked with yellow and grey boxes for the 
large and small deletion, respectively. Point mutations are indicated with a red 




Mutants of TriA and TriB were created through site-directed mutagenesis. C-
terminal truncations were created using forward and reverse primers designed to 
amplify the entire pBAD33-TriABC or pBAD33-TriAxBC plasmid, excepting the area 
to be deleted. Both forward and reverse primers contained an NdeI site for cloning, 
which preserved the overlapping start stop / start stop codon, but inserts a single 
isoleucine residue before termination. TriAxBC TriA-deletion mutants were made 
through the same method, but using a SpeI site, due to the presence of an NdeI site in 
the portion of AxB coding for the linker region. This change of restriction site inserts a 
serine and threonine before the AxB linker. TriAxBC TriB mutations were made using 
the same primers as TriABC TriB-mutations. All plasmids were confirmed via 
sequencing at Oklahoma Medical Research Foundation.  
 The new plasmids, pBAD33-TriA∆26BC, pBAD33-TriA∆47BC, pBAD33-
TriAB∆9C, and pBAD33-TriAB∆30C, as well as their pBAD33-TriAxBC equivalents, 
were transformed into E. coli JWW2. Cells were grown to mid-log phase before protein 
expression with 0.2% L-arabinose for 5 hours and subsequent cell lysis. Membrane 
fractions were collected and probed with anti-TriA and anti-TriB antibodies to 









Figure 1.5 – Expression of MP deletion mutants.  
Total membrane fractions of E. coli JWW2 cells carrying pBAD33-TriABC, pBAD33-
TriAxBC and their derivatives producing the indicated C-terminal deletions for TriA 
and TriB were isolated, total protein quantified and analyzed via SDS-PAGE and 
immunoblotting with anti-TriA and anti-TriB antibodies. 100 ng of total membrane 
protein was loaded for each sample.  
 
 Results indicate that with the exception of TriB in the pBAD33-TriA∆26BC 
construct, both TriA and TriB are expressed at levels detectable by anti-TriA and anti-
TriB antibodies in all unfused constructs. A corresponding mobility shift is seen as well, 
with deletion mutants appearing smaller compared to the wild-type TriA and TriB. The 
lack of TriB expression in the construct may result from the removal of an upstream 
Shine-Dalgarno sequence before the overlapping stop / start codon. In the pBAD33-
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TriA∆47BC construct, a modified Shine-Dalgarno site exists just upstream of the stop / 
start codon, likely preserving the expression of TriB in this construct. All deletion 
mutants created in fused TriAxBC express at levels comparable to the parental 
TriAxBC, but TriAxB∆9C and TriAxB∆30C do not exhibit the same gel shift observed in 
all other deletions. This could be because deletions in the C-terminal end of the fused 
protein do not significantly affect the electrophoretic mobility of the protein, or result in 
different protein-protein and protein-detergent contacts than the corresponding fused 
TriA or unfused TriB deletions (Rath, Glibowicka et al. 2009). 
 To test functionality of the TriABC and TriAxBC deletion mutants, constructs 
were co-transformed with pBAD-TriC into E. coli JWW2 and cells were tested for their 
susceptibility to SDS and triclosan. SDS and triclosan are currently the only identified 
substrates for TriABC. MICs were performed using the 2-fold dilution technique in 96-









 SDS (µg ml-1) Triclosan (ng ml-1)  
1 - 39 0.25 
2 TriABC  >2500 8 
3 TriAxBC  >2500 4 
    
4 TriAG350CBC  ≥2500 16 
5 TriABG339CC 39 1 
6 TriAG350CxBC >2500 8 
7 TriAxBG339CC  78 1 
    
8 TriAΔ26BC  39 <0.125 
9 TriAΔ47BC  39 <0.125 
10 TriABΔ9C  39 1 
11 TriABΔ30C  39 0.125-0.25 
12 TriAΔ26xBC  20 1 
13 TriAΔ47xBC  20 0.25 
14 TriAxBΔ9C  39 1 
15 TriAxBΔ30C  20 0.125-0.25 
    
 
Table 3 – C-terminal deletions in TriA and TriB impair complex function. 
Minimal inhibitory concentrations of SDS and triclosan were measured for calls 
producing various TriABC complexes expressed from pBAD33-based plasmids. 
 
 MIC measurements indicate that cells expressing protein containing any deletion 
made from the C-terminal end of either TriA or TriB have a severe defect in triclosan 
and SDS resistance, and this effect is seen regardless of if TriAB or TriAxB is used. 
However, the deficiency does not seem to be equal when making comparisons between 
TriA and TriB. Deletions made in the unfused TriA seem to completely abolish 
functionality of the complex, however the hypersusceptibility phenotype of cells 
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expressing TriA∆26BC is likely due to the lack of expression of TriB. Examination of 
the unfused TriB mutants show that cells expressing TriAB∆9C retain a low, but partial 
resistance to triclosan in contrast to cells expressing TriAB∆30C, which do not show any 
resistance to triclosan or SDS. The fused constructs follow this same pattern in which 
the cells expressing the small deletions retain some low level of functionality, but cells 
expressing large deletions of either TriA or TriB completely eliminate functionality of 
the complex.  
 
1.3.3 – C-terminal deletions affect interaction of TriA and TriB with TriC 
 Having established the functionality of TriA and TriB containing truncations in 
the MP domain, we then set out to determine which complex interactions were retained 
or abolished by these deletions. Since previous experiments showed that TriABC-
OpmH readily co-purifies together, we chose to express the various mutant constructs in 
tandem with histidine-tagged TriC and purify the transporter to establish complex 
interactions. This would allow us to determine if the MP domains are important for 
interaction with the transporter, as well as shed light on if TriA and TriB can 





Figure 1.6 – Co-purification of C-terminal TriA and TriB deletions.  
Membrane fractions containing the indicated plasmid-expressed TriA, TriB, or TriAxB 
mutants with TriChis were solubilized and purified using affinity chromatography. 
Proteins were quantified and 0.5 μg of purified TriChis was loaded onto SDS-PAGE gels 
and analyzed via immunoblotting and silver staining.  
  
 Co-purification experiments showed that TriA and TriB co-purify with TriC 
when expressed as full-length, unfused proteins. When expressed as separate 
polypeptides, deletions made in TriA do not affect the co-purification of TriB and vice 
versa. This indicates that binding of TriA and TriB to the transporter are independent 
events and are not dependent of the partner MFP. However, any deletions made in the 
MP domain of either TriA or TriB severely inhibit the ability of the truncated protein to 
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maintain interactions with TriC during the purification process. Only co-purified TriB∆9 
could to be detected with immunoblotting, indicating that it may interact with TriC, 
albeit to a lesser degree than wild-type.  
The fused TriAxB constructs provided new insight, as deletions made in TriA 
seem to affect co-purification with TriC much more than deletions made in TriB. 
Relative amounts of co-purified AxB seemed to be lower in TriA mutants than in TriB 
mutants, indicating that TriA and TriC may interact more strongly through the MP 
domain of the MFP than TriB and TriC.  
Finally, TolC could only be detected in purified fractions containing fused 
TriAxBC with no deletions made. This indicates that interaction between TriABC and 
TolC may be stabilized by the fused TriAxB, but unfused proteins do not stabilize 
interactions with a non-cognate OMF enough with that TolC can be detected by co-
purification and immunoblotting. Additionally, this result suggests that even a small 
deletion of MP domain residues disrupts interaction of AxBC with TolC, possibly due 
to an inability to recruit the OMF. Since all TriAxB deletion mutants co-purify with 
TriC, this suggests that the full-length MFP stabilizes the partner MFP in the complex 
with transporter interactions, but activity of the transporter requires both intact domains.  
1.3.4 – Analogous point mutations in the MP domain affect TriA and TriB 
differently 
 Results of co-purification experiments highlighted the importance of the MP 
domain in either MFP, but also suggested the idea that TriA and TriB do not share equal 
roles in the transport process. The disparate amounts of TriAxB co-purified when 
deletions were made in TriA versus TriB suggests that the strength of interactions, and 
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therefore binding sites, between TriA / TriB and TriC may be unique. Additionally, the 
very small amount of unfused TriB∆9 that was co-purified as compared to the 
undetectable TriA∆26 furthers the idea that TriB interactions with TriC are not as 
dependent on the MP domain as TriA interactions. To investigate further, we created 
TriA and TriB mutant proteins wherein a conserved glycine residue known to be 
important for MFP-transporter interactions in other efflux systems was mutated to 
cysteine. (Ge, Yamada et al. 2009) (Modali and Zgurskaya 2011).  
Using site-directed mutagenesis, G350 in TriA and G339 in TriB were 
converted to cysteine residues. Mutagenesis was carried out in pBAD33-TriABC and 
pBAD33-TriAxBC constructs. As previously described for deletion mutants, these point 
mutants were tested for expression, functionality, and ability to co-purify with TriC and 






Figure 1.7 – TriA, TriB, and TriAxB carrying MP domain point mutations are 
expressed.  
As previously described, point mutations were introduced into the MP domain of TriA 
and TriB encoded by their respective genes in pBAD33-TriABC and pBAD33-
TriAxBC plasmids. Mutated proteins were expressed in E. coli JWW2, induced with 
0.2% L-arabinose for 5 hours, membranes collected. 100 ng of total membrane extracts 
were analyzed via SDS-PAGE and immunoblotting with anti-TriA and anti-TriB 
antibodies. 
 
 Expression analysis shows that all proteins carrying mutations express at levels 
comparable to wild-type, and are readily visualized using antibodies specific for TriA 
and TriB. (Figure 1.10) Having established that point mutations in the MP domain do 
not affect expression of TriA and TriB in either the fused or unfused construct, MICs 
were determined as previously described in the Methods in order to establish 
functionality of the newly constructed proteins. (Table 4) Interestingly, MIC results 
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indicate that fused and unfused complexes containing TriAG350C are functional and 
protect the cell from both SDS and triclosan, whereas complexes containing TriBG339C 
yield MIC values comparable to empty vector, suggesting that TriBG339C-containing 
complexes are nonfunctional. This is in contrast to results from deletion mutants 
wherein C-terminal deletions in TriA affect the complex more drastically than 
corresponding deletions in TriB (Figure 1.9).  
To compare the effects of point mutations and deletion mutants on complex 
assembly, we utilized co-purification as previously described to isolate TriC and any 




Figure 1.8 – Co-purification of TriA and TriB carrying MP domain point 
mutations.  
Membrane fractions containing the indicated plasmid-expressed TriA, TriB, or TriAxB 
mutants with TriCHis were solubilized and purified using affinity chromatography. 
Fractions were quantified and 100 ng of purified TriCHis was loaded onto SDS-PAGE 
gels and analyzed via immunoblotting and silver staining.  
 
 Co-purification of TriA and TriB containing point mutants in the MP domain 
yielded interesting results when compared to MIC measurements. While TriAG350C 
seems to be functional in terms of efflux and TriBG339C is nonfunctional, the opposite 
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effect is seen in co-purification. The TriAG350C mutants in either fused or unfused 
constructs co-purify with TriC in limited amounts compared to the wild-type, and 
TriBG339C co-purifies at levels comparable to wild-type. As seen with deletion mutants 
(Figure 1.6), co-purification of one MFP in unfused constructs is not dependent on the 
ability of the partner MFP to co-purify. Additionally, neither fused point mutant is able 
to co-purify with TolC. Taken together, these observations indicate that while TriAG350C 
is functional, this point mutation reduces the overall stability of the complex with TriC. 
In contrast, TriBG339C is nonfunctional, but this point mutation has no effect on the 
assembly and stability of the complex.  
 Having established that TriA and TriB are unequal MFPs, we set out to identify 
the specific MFP-transporter contact interface and position the MFPs on the TriC 
transporter.  
 
1.3.5 Amber codon-incorporated AcrA is functional 
To determine the interfaces formed between TriA, TriB, and TriC during 
complex assembly, we first sought to establish a method that would serve as a novel, 
convenient way of establishing direct contact interfaces. For this purpose, we used 
photocrosslinking of proteins containing modified amino acid residues. Site-directed 
photocrosslinking has been developed as a method utilizing unnatural amino acids 
(UAA) that are photoreactive, such as p-benzoyl-L-phenylalanine (BzF) or p-azido-L-
phenylalanine (AzF) (Kauer, Erickson-Viitanen et al. 1986, Chin, Santoro et al. 2002). 
Utilizing various pEVOL plasmids, the necessary tRNA synthetase and suppressors are 
produced so that the amber codon UAG in mRNA is recognized to incorporate the UAA 
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into the produced protein (Young, Ahmad et al. 2010). Upon irradiation with UV light, 
a reactive form of the UAA is created that covalently binds with nearby C-H bonds, 
with different chemistries occurring depending on the utilized UAA. (Bayley and Staros 
1984, Dorman and Prestwich 1994) Koronakis et al 2009 reported crosslinking of the 
well-studied E. coli RND-type MFP AcrA and its associated transporter AcrB utilizing 
specific cysteine point mutants in tandem with functional crosslinkers, identifying likely 
interaction points between the transporter and the MFP. In order to establish our method 
with membrane-bound efflux transporters, we chose to first test the method with 
AcrAB. Residue R225 of AcrA was previously identified as an interface between AcrA 
and AcrB, and we chose this residue as a test for the photocrosslinking method to 
determine if this method could be adapted for efflux transporters, including TriA and 
TriB.  
The amber codon was introduced into the acrA gene encoded by the plasmid 
p151AcrAB (Table 1) utilizing site-directed mutagenesis (Quikchange Agilent). The 
result was then confirmed by sequencing (Oklahoma Medical Research Foundation). 
Then, the AcrAB-deficient E. coli strain JWW2 was transformed with the empty vector, 
wild-type p151AcrAB, and the mutated plasmid, p151AcrA*B containing the amber 
codon at position AcrA R225. To ensure the incorporation of an unnatural amino acid 
did not disrupt functionality of the complex, MICs of known AcrAB substrates were 












 (µg ml-1) 
Nor  
(µg ml-1) 
1 BW25113 WT >10000 64 64 128 
2 JWW2 (∆AcrAB) + pUC18 40 8 4 8 
3 JWW2 (∆AcrAB) + pUC151AcrAB >10000 32 32 64 
4 JWW2 (∆AcrAB) + 
pUC151AcrA*B 
40 8 4 8 
5 JWW2 (∆AcrAB) + 
pUC151AcrA*B + pEVOL 
>10000 64 64 128 
 
Table 4 - Amber-codon mutated AcrA is functional. 
MIC measurements of antibiotics in E. coli BW25113 and mutants carrying indicated 
plasmids. WT BW25113 contains chromosomally-encoded AcrAB and served as a 
positive control, while JWW2 contains no chromosomal AcrAB, and is transformed 
with either empty vector, plasmid-encoded AcrAB, or plasmid-encoded AcrAB with 
AcrA containing the amber codon at position R225. SDS – sodium dodecyl sulfate. Ery 
– Erythromycin. Nov – Novobiocin. Nor – Norfloxacin.  
 
Results show that AcrA with an amber codon is functional at a level comparable 
to wild-type AcrA expressed either from the chromosome or plasmid only when 
expressed in tandem from the pEVOL plasmid (Table 4). This is expected, as without 
pEVOL, the amber codon, UAG, acts as a stop codon within AcrA*. This results in a 
truncated version of the protein that ends at residue 225, and is expected to be non-
functional. Small 2-fold differences in MIC were observed between plasmid-encoded 
AcrA and chromosomal, but are not considered significant.  
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Having confirmed that an unnatural amino acid did not decrease functionality of 
the complex, we then grew E. coli JWW2 cells expressing pUC151AcrA*B, exposed 
whole cells to UV light and attempted to characterize crosslinked complexes. 
 
1.3.6 – Usage of the UAA BzF results in significant background incorporation of 
non-specific amino acids. 
As previously mentioned, JWW2 (pUC151AcrA*B + pEVOL) cells were grown 
in LB media containing the unnatural amino acid, p-benzoyl-l-phenylalanine (BzF) 
(BACHEM) at a concentration of 1 mM (Chin, Santoro et al. 2002). After collection, 
cells were exposed to UV light for times ranging from 1 minute to 60 minutes in order 
to determine conditions most effective for crosslinking. Controls included cells carrying 
plasmid-borne wild-type AcrAB, AcrA*B with no pEVOL plasmid, and AcrA*B with 
pEVOL grown in medium without BzF. Theoretically, no full-length AcrA should be 
produced in AcrA*B expressing constructs that do not have both pEVOL as well as 
BzF, as the amber codon acts as a stop codon in the absence of pEVOL, and should 
only code for the UAA BzF in the presence of pEVOL. After UV exposure, cells were 
lysed and membrane fractions collected as described in the Methods before protein 
amounts were quantified and normalized using SDS-PAGE with a BSA standard. 2 μg 
of total membrane extracts were then separated on a 12% SDS-PAGE gel, and subjected 





Figure 1.9 – AcrA*B contains significant incorporation of non-specific amino 
acids. 
JWW2 cells carrying plasmid-expressed variants of AcrAB and +/- pEVOL were grown 
in media with or without BzF and were exposed to UV light for the indicated amount of 
time and then subjected to lysis. Membrane fractions were collected, protein amounts 
were quantified and membrane fractions were analyzed by immunoblotting with anti-
AcrA antibody. The 10 minute p151AcrA*B time point is an identical sample to 10 
minute wild-type p151AcrAB due to a loading error. 
 
Results show that cells containing p151AcrAB encode full length AcrA, and the 
p151AcrA*B plasmid is unable to encode full-length AcrA as expected. However, 
contrary to expectations, cells containing AcrA*B and the pEVOL plasmid but grown 
in medium with no UAA added, full-length AcrA is seen running at the expected MW 
of ~45 kDa (Fig. 1.2). This indicates that a significant amount of background 
incorporation of other amino acids occurs, resulting in AcrA* containing a non-specific 
amino acid at position 225. This likely also occurs in cells grown with BzF, resulting in 
a very low amount of AcrA* containing BzF. While UAG codon should only encode 
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for the charged tRNA carrying BzF, which is produced via the pEVOL plasmid, non-
specific incorporation of other natural amino acids, likely tyrosine, can result in the 
tRNA incorporating natural amino acids into the protein (Chin, Santoro et al. 2002).  
To adapt, we investigated another UAA, p-azido-L-phenylalanine (AzF). AzF is 
a slightly smaller UAA than BzF with an MW of 206.2 g/mol as compared to 269.3 
g/mol, and other experiments have shown better incorporation of AzF into other 
experiments utilizing this same technique, likely due to more efficient binding of AzF 
and the cognate tRNA. (Young, Ahmad et al. 2010) 
 
1.3.7 – AcrA*B forms complexes upon exposure to UV light 
In order to improve the fidelity of UAA incorporation into AcrA*B, we not only 
utilized the UAA AzF rather than BzF, we also grew cells in YT media, as described in 
previous publications (Farrell, Toroney et al. 2005). As previously described, proteins 
were produced by JWW2 cells and whole cells were exposed to UV light before cell 
lysis and membrane fractionation. Total membrane proteins were then quantified and 
loaded onto 12% SDS-PAGE gels for immunoblotting. For proteins visualized using 
anti-AcrA, 2 μg of total membrane extracts were loaded and anti-poly His proteins were 





Figure 1.10 – AcrA*B forms specific complexes when expressed with AzF. 
JWW2 cells carrying plasmid-expressed variants of AcrAB and +/- pEVOL were grown 
in media with or without AzF and were exposed to UV light for the indicated amount of 
time and then subjected to lysis. Membrane fractions were collected, protein amounts 
were quantified and membrane fractions were analyzed by immunoblotting with anti-
AcrA and anti-poly His antibodies. An observed band between 100-130 kDa is 
indicated by an arrow. 
 
While some background incorporation still remained, the overall level of AcrA* 
produced without AzF is lower than wild-type AcrA, indicating that a higher efficiency 
of UAA incorporation was occurring (Figure 1.10). Additionally, when exposed to UV 
light, a new band between 100-130 kDa appeared in the samples isolated from cells also 
containing pEVOL and grown in the medium supplemented with AzF. A band of 
similar size is also observed in the WT AcrAB complex in lesser amounts, indicating 
that the crosslink may be stabilizing a biologically relevant complex.  
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In order to further characterize and establish this band, crosslinked protein was 
then purified from cells using His-bind resin charged with Cu2+. Proteins were eluted 
with an imidazole gradient, and fractions eluted with 100 and 500 mM imidazole were 
separated on an 8% SDS-PAGE gel. After separation and immunoblotting, AcrA-
containing bands were visualized using anti-AcrA antibody.  
 
 
Figure 1.11 - AcrA* can be purified. 
Membrane fractions containing AcrA variants, as well as AcrA* +/- UV exposure were 
solubilized in 5% Triton X-100. Insoluble fractions were removed by high-speed 
centrifugation and solubilized proteins were loaded onto a His-bind column. Bound 
proteins were eluted using 100 mM and 500 mM imidazole and quantified before 
analysis by SDS-PAGE and anti-AcrA immunoblotting. An indicated band between 




Again, a band reacting with anti-AcrA antibody is observed at a MW between 
100-130 kDa in cells irradiated with UV light, but not in UV- cells. (Figure 1.11) The 
composition of this crosslinked band remains unknown as the observed size is difficult 
to reconcile, given the molecular weights of AcrA and AcrB, at approximately 45 kDa 
and 113 kDa, respectively. An AcrA crosslink-stabilized dimer would run below this 
observed band at ~90 kDa, and any AcrB-containing complexes with AcrA would be of 
a size greater than 150 kDa. There is the possibility of larger AcrB-containing 
complexes existing, but at amounts too low to detect with anti-AcrA or anti-poly His 
antibodies.  
Thusly, we are able to observe some cross-linked complexes between AcrA and 
another component that closely interacts with residue R225. This indicates that 
photocrosslinking is possible using unnatural photoreactive amino acids and membrane-
localized proteins. Additionally, the UAA AzF showed a greater efficiency of specific 
photocrosslinking and specific high molecular weight bands as compared to the UAA 
BzF. However, we are unable to confirm photocrosslinking AcrA residue R225 and 
AcrB. This could be because AcrA R225 does not directly contact AcrB, or it could be 
obscured by other protein structure within AcrA. Further studies of MFP-transporter 
interactions are needed to determine the MFP-transporter interface, but photoreactive 






 MFPs are known to play an important role in the assembly and function of 
efflux systems, but the extent and specifics of this role remain uncertain. For example, 
MFPs are known to stimulate transporters as well as recruit OMFs in order to facilitate 
transport into extracellular space (Zgurskaya, Weeks et al. 2015). Additionally, very 
little is understood about how components of these transporters coordinate the efflux 
process. The MP and β-barrel domains are thought to primarily govern interactions 
between the MFP and the transporter component, whereas the lipoyl and α-helical 
domains principally interact with the OMF (Zgurskaya, Weeks et al. 2015). The study 
of these interfaces could provide a useful insight into the mechanism of these 
transporters as well as pave the way for future inhibitor and targeted drug design.  
Here, we show that two distinct membrane fusion proteins, TriA and TriB 
function together as a heterodimer with unique binding sites and interfaces between the 
MP domain of the MFPs and transporter. We also show that a covalently linked 
heterodimer of TriAxB is functional with TriC. Thus, TriA and TriB function in a 1:1 
ratio and their functional unit is a heterodimer that most likely trimerizes in the fully 
assembled complex. This result provides the strongest evidence yet that the functional 
unit of MFPs is a dimer, even in other efflux complexes. Previous studies focused on 
crystallographic structures of MFPs, such as the P. aeruginosa MexA, and the E. coli 
MFPs MacA and AcrA (Akama, Kanemaki et al. 2004) (Mikolosko, Bobyk et al. 2006) 
(Yum, Xu et al. 2009), which suggested the functional dimer unit, but did not provide 
strong evidence as early hydrodynamic studies and size-exclusion chromatography 
showed monomeric MFPs. (Zgurskaya and Nikaido 1999) (Tikhonova, Dastidar et al. 
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2009). The functionality of the AxB fusion protein combined with more recent kinetic 
data regarding the stability of MFPs (Tikhonova, Yamada et al. 2011) provide strong 
evidence that MFPs interact with one another as a dimer, and function as repeating 
dimer pairs within the assembled complex.  
Additionally, we show that analogous deletions of conserved residues in the MP 
domain affect TriA and TriB differently. When deletion mutants are produced as 
separate polypeptides, only TriB∆9 is able to even partially rescue the susceptibility of 
JWW2. Additionally, deletion mutants in individual proteins do not affect interactions 
between the partner MFP and TriC. Thus, C-terminal deletions significantly weaken the 
association between MFPs and transporters, but binding to TriC is an independent event 
for each MFP. Taken into account with the data regarding TriAxB, this suggests that 
MFPs are able to bind the transporter independently of one another, and then interact in 
a dimeric fashion to form a functional efflux complex.  
How the complete RND efflux complex assembles is a subject of intense 
investigation. Current crystal structures of the CusBA efflux complex place the 
individual protomers of the MFP CusB differently on the transporter CusA, primarily 
between the MP and the β-barrel domains. (Du, Wang et al. 2014). Additionally, the 
cryo-EM-based structure of the complete AcrAB-TolC complex (Su, Long et al. 2011) 
shows similar positioning of AcrA on the transporter AcrB. This difference in binding 
sites could suggest that the affinity of MFPs to transporters could be different 
depending on the protomer. Our experiments showed that all covalently linked TriAxB 
constructs were co-purified with TriC, but the amounts differed drastically depending 
on which MFP contained a deletion. Deletions in TriA of the fused protein had a larger 
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effect on interactions with TriC, whereas deletions in TriB were purified in near wild-
type levels.  
This result suggests that the affinity of the full-length MFP is enough to 
compensate for the deletion mutant, but since all mutants were essentially 
nonfunctional, this compensation is only enough to maintain interaction, and not 
enough to maintain activity of the pump. The discrepancy between the amount of co-
purified TriAxB when comparing TriA and TriB deletions could stem from the specific 
contact interfaces formed between the MFPs and transporter, indicating that TriA 
interacts with the transporter more through the C-terminal end of the MP domain, and 
interactions between the transporter and TriB are not as dependent on this section of the 
MFP. This corresponds with MIC data, in which TriB∆9 was the only deletion mutant 
able to display even partial functionality. Additionally, since all MP domain mutants 
lost their ability to co-purify TolC from E. coli, we can conclude that the MP domain is 
important for assembly of the complete transport complex. While the MP domain is not 
thought to principally interact with the OMF, the MP domain could be important for 
translating conformational changes that recruit the OMF to the complex, and deletions 
therein abolish the ability of the complex to strongly interact with TolC.  
In addition to deletion mutants, site-specific mutations in the MP domain affect 
TriA and TriB differently. Point mutations in TriA, produced either as a fused protein or 
separate polypeptides, were functional and able to provide resistance against SDS and 
triclosan. However, the analogous point mutation in TriB is unable to protect against 
SDS and triclosan, providing further evidence that the C-terminal domains of TriA and 
TriB interact with TriC differently. Interestingly, point mutations in either fused or 
 
80 
unfused TriB seem to not have any effect on interactions with TriC, but both fused and 
unfused TriA mutants co-purified in a lower amount than wild-type. This is 
correspondent to results from C-terminal deletions in which deletions within TriA co-
purify in lower amounts than deletions in TriB. Thus, TriBG339 is important for complex 
function but does not affect assembly of the MFP-transporter complex, whereas 
TriAG350 is not essential for function, but affects overall stability of the complex. No 
point mutations were able to co-purify TolC, indicating that again, interactions between 
the MFP and TriC are important for recruitment of the OMF.  
The model of MFP-dependent transport shows that the transporter and MFP 
exist in complex, awaiting stimulus for the MFP to recruit the OMF (Zgurskaya, Weeks 
et al. 2015). This stimulus could be binding of substrate to the transporter. Taking this 
into account, our results indicate that deletion of the C-terminal residues of the MFP 
abolish the ability of the MFP to recruit the OMF, possibly because the MFP is no 
longer able to respond to stimulus from the transporter, resulting in an inability to make 
the conformational changes necessary for TolC recruitment. Point mutations in TriB 
also yield a non-functional complex that is unable to recruit TolC, indicating this 
residue is required for assembly of a stable complex. Interestingly, the functionality of 
the analogous residue in TriA indicates that it is not required for complex assembly, but 
this complex is unable to co-purify TolC. This could indicate that mutation of this C-
terminal residue in both TriA and TriB reduces stability of the overall complex, but in 
TriB it either abolishes the ability to recruit TolC entirely, or possibly results in a defect 
in different function of TriB, such as transporter stimulation. 
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Together, these results indicate that in the interface between MFPs and cognate 
transporters, TriA and TriB perform separate roles in the transport process. RND-type 
transporters relies on a functional rotation in which each protomer of the trimeric RND 
transporter cycles through three conformations in order to bind and extrude substrate 
(Pos 2009). Taking this into account, it is possible that as the individual protomers of 
the RND transporter transition between the open, loose and tight conformations, the 
individual protomers of the MFP may be responsible for translating these 
conformational changes to the OMF in such a way that one MFP is responsible for 
opening the OMF, and the other MFP responsible for stimulation of the transporter 
while the complex is assembled. Changes in the MP domain may abolish this ability to 
translate these conformational changes, rendering the complex nonfunctional. This has 
implications for other transporters, where instead of TriA and TriB performing separate 
roles, two different MFP molecules would be responsible, possibly for stimulation of 
the transporter and engagement of the OMF.  
It is possible that since TriA and TriB are of different lengths, the larger 
deletions in TriA are the source of the more drastic assembly and function changes, but 
sequence homology shows that the C-terminal region of TriA and TriB share these 
common residues with many other MFPs, and likely have a very similar structure to 
common MFPs (Figure I.3) (Zgurskaya, Weeks et al. 2015). Additionally, in the fused 
protein it is possible that a C-terminal deletion in TriA changes the positioning and 
placement of TriB by way of shifting the second MFP, thereby changing and restricting 
how the fused protein is able to interact with the transporter. 
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We also utilized a method to link components of efflux transporters by the 
insertion of photoreactive amino acids into the genetic code. To establish the method, 
we used the well-studied AcrAB transporter from E. coli, and attempted to 
photocrosslink AcrA to its cognate transporter AcrB. We showed that AcrA* forms new 
high molecular weight complexes on exposure to UV light, running at approximately 
120-130 kDa (Figure 1.11). This band was also observed in the WT complexes at a 
much lower level, indicating that the formed complex may be of biological relevance. 
The identity of these complexes is unknown and difficult to reconcile, given the 
molecular weights of AcrA and AcrB at ~45 and ~115 kDa, respectively. Since samples 
were not boiled or run under reducing conditions, it is possible that the observed band is 
an AcrB-containing complex, but the discrepancy between observed and expected sizes 
makes it impossible to conclude that the observed complex contains AcrB.  
The observed size could also correspond to an AcrA trimer, but the model of 
MFP oligomerization (Zgurskaya, Weeks et al. 2015) postulates that the functional unit 
of the MFP is a homodimer which then further trimerizes to form a hexameric 
functional MFP complex. Based on this current model, while possible, it is difficult to 
conclude that a ~135 kDa trimer of AcrA would form from photocrosslinking of R225. 
As an AcrAB complex has not been visualized with sufficient resolution to determine 
the exact interface between AcrA and AcrB, it is possible that residue R225 does not 
contact AcrB closely enough for UAA photocrosslinking to covalently link the proteins. 
While (Symmons, Bokma et al. 2009) reported that AcrA and AcrB crosslink at residue 
R225, this publication utilized bifunctional crosslinkers with spacer arms of 6.8 
angstroms and 15.6 angstroms to link AcrA and AcrB. The photoreactive amino acids 
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used here have no spacer arms and impose a distance requirement of approximately 3.0 
angstroms (Chin, Santoro et al. 2002). This could explain the discrepancy seen between 
the crosslinking results of previous publications and the experiments performed here. 
However, we can conclude that AcrA-containing complexes were formed, and that this 
method can be used to photocrosslink transporter components. However, due to the 
distance requirements imposed by the UAA crosslinking (Chin, Santoro et al. 2002), 
residues should be selected based on the closest possible interaction between complex 
components. 
Future experiments with TriA and TriB could elucidate the MFP-transporter 
interface even further. While we have determined that TriA and TriB have different 
binding sites on TriC, still little is known about precise MFP placement on the fully 
assembled RND transporter. Modeling of the interfaces between TriA, TriB, and TriC 
can identify possible interaction points, which would provide a clearer picture of the 
interactions between complex components. To further characterize these interactions, 
site-specific crosslinking can be performed to elucidate the exact positioning of TriA 
and TriB on TriC. Residues predicted to contact the transporter can be identified both 
through using homologous residues from other MFP-transporter crosslinking 
experiments as well as molecular modeling. Using the method described here, TriA, 
TriB, and TriC with specific residues mutated to the amber codon can be exposed to UV 
light and photocrosslinked together in such a way that the specific contact interfaces 
between each MFP and the transporter can be characterized, allowing us to fully 
understand the placement of MFPs on the transporter.  
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Chapter 2. Interactions between OMFs and the MFPs TriA and TriB 
2.1 Abstract 
 MFPs are known to play a role in the recruitment of outer membrane factors, 
and depending on a model, MFPs are believed to interact with OMFs anywhere from a 
full integration of the α-helical domains to a limited tip-to-tip interface. This study 
again focuses on the paired MFPs TriA and TriB and their interactions with other 
complex components. Here, I investigate their interactions with the non-cognate E. coli 
OMF TolC as well as the cognate P. aeruginosa OMF OpmH. As a paired MFP known 
to function as a heterodimer, TriA and TriB are expected to occupy different binding 
sites on the OMF. To gain insight into the interactions between the MFPs and the OMF, 
I created deletion mutants of the CC domain in TriA and TriB produced individually or 
as a fused polypeptide, and tested these mutants through functional MIC studies as well 
as co-purification steps that shed light on the assembly of the transporter. Results 
showed that deletions disrupt complex assembly with TolC in E. coli, but have no effect 
on interactions between the MFPs and TriC. Additionally, I created site-specific point 
mutants of conserved residues near the tip of the CC domain that have been identified 
as important for MFP-OMF interaction. I then tested the effects of these mutations on 
the native OMF, OpmH in P. aeruginosa and found similar results to TolC in E. coli. 
Results show that these point mutations affect TriA and TriB differently, and provide 
further evidence that TriA and TriB occupy two non-interchangeable binding sites 






While the MP domain of MFPs is thought to principally govern interactions 
between the IMF and MFP, OMFs are also known to closely interact with MFPs, except 
interactions seem to be governed mainly through the α-hairpin domain (Zgurskaya, 
Weeks et al. 2015). These interactions remain uncharacterized, and data published so 
far do not take into account a model in which each MFP protomer could have a different 
role and binding site. Current models of the resting state of the transporter place the 
MFP and transporter together, and upon substrate binding, the OMF is recruited by the 
MFP to allow efflux before dissociation of the OMF (Chuanchuen, Murata et al. 2005, 
Tikhonova, Yamada et al. 2011). The process in which the MFP recruits the OMF 
results in two distinct events occurring. Firstly, the MFP undergoes conformational 
changes when interacting with an OMF, and that those conformational changes are 
linked to the stimulatory activities of the MFP (Ge, Yamada et al. 2009, Modali and 
Zgurskaya 2011). Secondly, OMF binding to a MFP-transporter complex is proposed to 
lead to an opening of the OMF channel (Weeks, Celaya-Kolb et al. 2010, Janganan, 
Bavro et al. 2013). This overall model places the MFP in a crucial role of directing 
movement of substrate throughout the complex, but the specifics of this role are not 
well understood. 
Kinetic experiments have shown that the affinity of the MFP to either the 
transporter or OMF changes as a function of pH (Tikhonova, Dastidar et al. 2009, 
Tikhonova, Yamada et al. 2011), indicating that changes in pH could trigger 
conformational changes in MFPs associated with the efflux process. As with 
MFP:transporter interactions, the ratio of MFP:OMF monomers is 6:3, resulting in two 
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MFP subunits contacting a single OMF protomer. This again indicates that the MFPs 
would have two separate binding sites to bind the OMF in the fully assembled complex. 
Existing crystal structures and models of MFP-OMF interactions place the two MFPs in 
the grooves of the OMF protein, specifically in the inter- and intra-protomer grooves of 
the OMF. This supports the idea of MFPs having two distinct binding sites as well as 
distinct functions between the individual MFPs.  
 The homotrimeric E. coli OMF TolC functions with various efflux pumps from 
multiple superfamilies, and we previously showed that it functions with the non-cognate 
P. aeruginosa TriABC transporter when expressed together in E. coli. (Table 3). TolC 
is a 12 β-strand barrel, which is 30 Å wide and contains six loops exposed to the 
surface, and extends into the periplasm as a 140 Å long α-barrel (Koronakis, Sharff et 
al. 2000). The periplasmic end of the α-barrel forms an aperture that is thought to 
change conformation upon binding the MFP that allows the movement of substrate 
through the OMF. This conformational change consists of a twist and dilation of the 
helicies on the periplasmic tip, thereby “opening” the channel on both ends (Bavro, 
Pietras et al. 2008, Pei, Hinchliffe et al. 2011). This transition between “open” and 
“closed” states of OMFs defines the transition between resting and active states, in 
which the periplasmic tip of the OMF changes conformation upon OMF-MFP 
interaction.  
Models of interaction between OMFs and transporters are under debate, as some 
evidence shows that AcrB is able to directly contact TolC (Murakami, Nakashima et al. 
2002) and other, recent structural evidence shows that there is no direct interaction 
between AcrB and TolC (Du, Wang et al. 2014). Additionally, transporters from ABC 
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and MF superfamilies lack a large periplasmic domain and would be unable to directly 
interact with the OMF (Lu and Zgurskaya 2013). The goal of this study is to 
characterize the specific interactions between MFPs and OMFs, as current models of 
MFP-dependent transport lack specific information on how MFPs interact with OMFs, 
and do not take into account the possibility of an unequal MFP dimer. 
In this study, we focused on the triclosan efflux complex TriABC, introducing 
site-specific mutations as well as deletions within the coiled-coil region and analyzed 
the effects of mutations in TriA and TriB on functionality as well as complex assembly. 
Again, we utilized the E. coli model in which TriABC functions with the promiscuous 
OMF TolC in order to provide resistance against SDS and triclosan. Additionally, we 
investigate assembly of the complex in the native P. aeruginosa via co-purification of 






Figure 2.1 – Model of TriABC-OpmH interactions.  
A. Top-down view of the complex. Individual protomers are distinctly colored. B. 
Bottom-up view of the complex. C. Side view of the complex. D. Interactions between 
single protomers of TriA, TriB, and OpmH. TriA is colored in green, TriB is colored in 
cyan, and OpmH protomers are colored in orange / dark green. Residues selected for 





2.3.1 – Mutations in the coiled-coil domains affect TriA and TriB function 
differently. 
Previous studies implicate the α-helical hairpin domain in the recruitment of 
OMFs and assembly of a functional RND-MFP-OMF complex. (Chuanchuen, Murata et 
al. 2005, Lobedanz, Bokma et al. 2007, Tikhonova, Dastidar et al. 2009) However, 
some MFPs such as BesA and CusB (Greene, Hinchliffe et al. 2013) have unusual or 
even entirely missing α-helical domains. Despite this, both MFPs are able to function 
with an OMF in order to extrude substrate. To investigate the roles of the CC domain of 
TriA and TriB in the recruitment and function of the complex with TolC, the coiled-coil 
of each MFP was removed, leaving only the native CC turn linking the two halves of 
the lipoyl domain. This drastic change would allow characterization of the CC domains 
of TriA and TriB, determining if the domain is required in both MFPs. 
Additionally, point mutations were made through site-directed mutagenesis, 
changing the highly conserved arginine residues of R130 in TriA and R118 in TriB near 
the tips of the α-helical hairpin to aspartic acid. Aspartic acid was chosen to contrast the 
basicity of the native arginine. These conserved arginine residues have been shown to 
be essential for function of efflux complexes and interaction of other MFPs with OMFs. 
Specifically, the MFPs MacA and AcrA both require this conserved arginine residue to 
bind TolC, despite their cognate transporters being in the ABC and RND families, 
respectively. (Kim, Xu et al. 2010, Xu, Sim et al. 2010) If TriA and TriB interact with 
TolC in the same way as these MFPs, this conserved arginine residue may be required 
for their interactions, but if TriA and TriB retain different interactions with the OMF, 
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this residue may only be required for one of the MFPs. As with MP domain mutations 
and deletions, these variants were produced in TriA and TriB proteins separately as well 
as a part of the covalently-linked TriAxB complex. 
The newly created pBAD33-TriABC deletion mutants, pBAD33-TriA∆ccBC, 
pBAD33-TriAB∆ccC, as well as the point mutants pBAD33-TriAR130DBC and pBAD33-
TriABR119DC were transformed into E. coli JWW2 and tested for expression using 0.2% 
arabinose as an inducer. After membrane fractionation, extracts were analyzed using 
immunoblotting. 
 
Figure 2.2 – Expression of TriA and TriB containing CC deletions and point 
mutations. 
100 ng of membrane extracts of JWW2 cells expressing TriABC and TriAxBC variants 
were analyzed using SDS-PAGE followed by immunoblotting with antibodies specific 




 Results indicate that all α-helical deletion mutants as well as point mutations are 
expressed in E. coli, although CC deletions in unfused TriA and TriB result in a 
noticeably reduced level of detectable protein. (Figure 2.2) 
Having established that all variants are expressed in our model system, we tested 
functionality of these mutants using MICs with the previously established substrates of 
the TriABC efflux pump, triclosan and SDS. 




 SDS (µg ml-1) Triclosan (ng ml-1)  
1 - 39 0.25 
2 TriABC  >2500 8 
3 TriAxBC  >2500 4 
    
4 TriAR130DBC  39 <0.125 
5 TriABR118DC  >2500 2 
6 TriAR130DxBC  39 <0.125 
7 TriAxBR118DC   >2500 1-2 
    
8 TriAΔCCBC  39 <0.125 
9 TriABΔCCC  39 <0.125 
10 TriAΔCCxBC  39 4 
11 TriAxBΔCCC  39 4 
    
 
Table 5 – Mutations and deletions in the coils of TriA and TriB affect complex 
function differently. 
  
MIC measurements showed that both TriA∆cc as well as TriB∆cc were unable to 
complement the efflux-deficient JWW2 E. coli strain either as a fused or unfused 
complex. (Table 5) This result indicates that the α-helical domain is required for 
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complex function in both TriA and TriB. Of extreme interest, analogous point mutations 
in the CC domain of TriA and TriB affected each protein very differently. Complexes 
assembled with either TriBR118D or TriAxBR118D were fully functional. In contrast, 
complexes with TriAR130D and TriAR130DxB failed to provide resistance against either 
SDS or triclosan, indicating that this highly conserved residue is essential for the 
function of TriA but not TriB. This provides further evidence that these MFPs utilize 
different binding sites on the OMF, and have different functional roles in the efflux 
process. 
 
2.3.2 – Mutations in the coiled-coil domain of TriA and TriB affect complex 
assembly differently. 
 Having established the lack of functionality of TriA∆CC and TriB∆CC mutants as 
well as the inequality of point mutations, we set out to establish how these changes 
affect the assembly of the efflux complex. The co-purification approach seen previously 
with MP domain mutations was utilized in which TriCHis was expressed from pBAD-
TriC in JWW2 E. coli alongside with pBAD33-based variants of TriABC and TriAxBC, 
and the histidine-tagged TriC was purified using affinity chromatography on His-bind 





Figure 2.3 – Mutations in the CC domain of TriA and TriB do not affect co-
purification with TriC. 
Membrane fractions containing the indicated plasmid-expressed TriA, TriB, or TriAxB 
mutants with TriChis were solubilized and purified using affinity chromatography. 
Fractions were quantified and 0.1 μg of purified TriChis was separated by SDS-PAGE 
and proteins were analyzed via immunoblotting and silver staining.  
  
 Co-purification results show that neither substitutions nor deletions affect the 
ability of TriA or TriB to co-purify with TriC, either in a fused or unfused form. 
(Figure 2.3) Thus, as expected, mutations in the CC domain of MFPs do not affect 
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interactions with the transporter, even when the CC domain is removed entirely. We did 
find, however, that interactions with TolC were highly sensitive to deletions and 
substitutions in the CC domain. The only complex able to co-purify TolC was 
TriAxBR118D, indicating that TriAR130D disrupts interactions between the MFP and 
OMF. This is consistent with both MIC data, as the TriAR130D mutant was shown to be 
non-functional, as well as data described in Chapter 1 showing that only the TriAxBC 
complex is able to stabilize interactions with TolC to a degree that can be shown with 
co-purification. Therefore, while TriBR118 is not essential for complex formation and 
functionality, the analogous and highly conserved TriAR130 is indeed required, and 
distinguishes the two MFPs in formation of a functional TriABC-OMF complex. 
 
2.3.4 – Mutations in the coiled-coil domain of TriA and TriB affect interactions 
with OpmH differently 
 After investigating complex assembly in E. coli, we then set out to characterize 
interactions of the coil mutants with the native OMF, OpmH of P. aeruginosa. Previous 
experiments utilized the transporter as “bait,” relying on continuous interactions 
between the MFP and transporter in order to obtain co-purified protein. It would be 
advantageous to purify the complex from the opposite direction, and utilize the OMF as 
“bait,” thereby focusing on interactions between the MFP and OMF. Due to the 
difficulty of co-purifying TolC with unfused TriABC (Figure 1.6) we chose to utilize 
the native OMF, OpmH as “bait.”  
The pBAD33-based constructs were subcloned into pBSPII, and the resulting 
plasmids were transformed into P. aeruginosa JWW6, which expresses OpmHHis under 
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an arabinose-inducible promoter. (Table 1) OpmHHis was induced using 1.0% L-
arabinose, and the CC mutants were constitutively expressed from the pBSPII plasmid 
before cell lysis and affinity chromatography to purify OpmHHis. Difficulty subcloning 
pBSP-TriA∆CC resulted in an inability to test this mutant with OpmH. 
 
Figure 2.4 – Mutations in the CC domain of TriA and TriB affect interactions with 
OpmH differently  
Membrane fractions of P. aeruginosa JWW6 carrying the indicated pBSP-expressed 
TriABC CC mutations were solubilized in 2% DDM overnight and subjected to affinity 
chromatography to purify OpmHHis. Fractions were quantified and 0.1 μg of purified 
OpmH was separated by SDS-PAGE and proteins were analyzed via immunoblotting 
and silver staining. 
 
 Results show that in P. aeruginosa, mutation of the conserved residue R130 in 
TriA results in an inability of TriA to co-purify with the rest of the complex, but the 
corresponding residue, R118 of TriB retains interactions with the complex during co-
purification. Additionally, deletion of the coil domain of TriB results in an inability of 
any complex components to co-purify, but among fused protein constructs, all proteins 
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were able to co-purify in wild-type amounts. Interestingly, in the TriAR130D mutant, 
while TriA was unable to co-purify with OpmH, TriC co-purifies with TriB and OpmH. 
This indicates that with the native OMF, TriB is required to assemble the complex, but 
both MFPs are required for function. These mutants were also tested for functionality, 
and results showed non-functionality of all tested coil deletion mutants, but of the point 




 The α-hairpin domain of MFPs has been shown to interact with OMFs, mainly 
through the minor and major grooves of the OMF (Misra and Bavro 2009, Zgurskaya, 
Weeks et al. 2015). The three-fold symmetry of the transporter complex indicates that 
one OMF protomer will contact MFPs through the inter- and intra-protomer grooves, 
for an overall stoichiometry of 2 MFP: 1 OMF. This indicates that there is more than 
one binding site between MFPs and OMFs, and in single MFP systems, different 
binding sites could impart different functions upon the MFP, allowing the same protein 
to fulfill multiple roles. Using TriABC, we show that a paired MFP transporter has 
unique binding sites for each MFP, and that each MFP may have a unique role in the 
transport process.  
 Deleting the CC domain from either fused or unfused TriB predictably 
eliminated transporter function, likely by preventing recruitment of the OMF by the 
MFP-IMF complex. This result is also seen in the fused TriA coli mutant. While we 
were unable to test the unfused TriA mutant due to difficulties in subcloning, we can 
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speculate that the same effect would be seen, as even the mutation of a single residue in 
the CC domain of TriA eliminated transporter function. This is supported by co-
purification data in which the TriC transporter is able to co-purify all of the coiled-coil 
deletion and point mutants, whether expressed individually or as a single polypeptide, 
but unable to co-purify TolC. Thus, the CC domains of TriA and TriB are each required 
for complex function, but have no bearing on interaction with TriC, meaning that 
interaction of the MFP with the transporter is entirely independent of the CC domain.  
Point mutants of a conserved arginine residue near the tip of the CC domain 
affected TriA and TriB differently both in terms of complex assembly as well as 
function. When TriA is expressed as TriAR130D in either the fused or unfused complex, 
we see an inability of the complex to provide resistance against triclosan and SDS, as 
well as a failure of TriC to purify with TolC, likely due to disruption of the functional 
linkage between the MFP and OMF. In contrast, TriBR118D retains all the ability and 
functionality of the wild-type protein, and is the only mutant in this study able to co-
purify the OMF TolC. As the CC domains of TriA and TriB have the same length, 
either MFP could theoretically occupy either the inter- or intra-protomer grooves of the 
OMF TolC. Our results show here that when expressed separately, both CC domains are 
required for full interaction of the complex, but a point mutation in a conserved arginine 
residue on the tip of the TriA CC domain will inactivate the complex, but the analogous 
mutation in TriB does not affect complex function or assembly. Therefore, TriA and 
TriB interact very differently with TolC, and consistent with previous publications, the 
MFPs likely function as a dimeric unit that further trimerizes around the OMF in order 
to create a functional hexameric arrangement of MFPs.  
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Our results also indicate that interactions between TriABC and TolC are similar 
to that of TriABC and OpmH. When the same point and deletion mutants used with 
TolC were expressed and co-purified in P. aeruginosa using OpmHHis as a bait, results 
showed that again, the point mutation TriAR130D was unable to maintain interactions 
with the OMF through the purification process, whereas TriBR118D showed no changes 
from wild-type protein. Interestingly, while the fused AxB-based mutants were unable 
to co-purify TolC in E. coli with the exception of TriBR118D, all pBSP-based AxB 
mutants were able to co-purify with OpmHHis in P. aeruginosa.
 This could be due to 
more specific interactions between TriAB and OpmH than TriAB and TolC. These 
more specific interactions would also explain the interesting result seen in the co-
purification of TriAR130D. Here, no TriA was seen in the purified sample, but TriB and 
TriC were co-purified with OpmH. This indicates that when utilizing the native OMF, 
TriB is able to assemble the complex and maintain interactions with TriC even in the 
absence of TriA. It is not known if TriA can provide the same effect in the absence of 
TriB.  
Also of interest, no components of TriAB∆CCC were detected in purified OpmH 
fractions. This indicates that the coil domain of TriB is required to establish TriA-OMF 
interactions. This is in agreement with the E. coli-based TriC purifications, as any 
changes in the coil domain of either protein eliminate the ability of the OMF to co-
purify with the transporter. Unfortunately, we were unsuccessful in obtaining a pBSP-
based TriA∆CCBC mutant, and this construct could shed light on if full-length TriA is 
also required to establish TriB interactions. If so, then the paired MFPs must work in 
concert to recruit the OMF. Taken in light of our MP domain mutations, we have 
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established that MFPs are able to bind the transporter independently, but at least full-
length TriB is required to assemble with the OMF, and studies of TriA∆CCBC can shed 
more light on the specifics of interaction between TriAB and OpmH. 
 Taking all CC domain results in tandem with studies regarding the MP domain, 
it appears that point mutations in conserved residues of TriA affect its engagement with 
the OMF more than with the IMF. Correspondingly, analogous mutations in TriB seem 
to have more adverse effects with the transporter than with the OMF. However, this 
would seem to be in contrast to some deletion mutant data, in which TriB∆9 is partially 
function, but TriA∆26 is not. It is more likely though that TriA∆26 is nonfunctional simply 
due to the lack of TriB expression in that specific mutant. Considering the roles of the 
MFP, it seems possible that both TriA and TriB are involved in complex assembly, as 
removal of the C-terminal domain of either protein results in an inability to recruit 
TolC. Considering the point mutants, it also appears that TriA is more involved with the 
OMF, although it is unclear if this involvement is specific to either recruiting or 
opening of the OMF. Additionally, it seems that TriB, while involved with assembly of 
the complex, is more engaged with the transporter. 
What is clear, however, is that TriA and TriB occupy different binding sites on 
both TriC as well as TolC and OpmH, and that they retain unique roles in the transport 
process. We conclude here that TriA and TriB are unique membrane fusion proteins that 
occupy specific binding sites on the OMF. We can speculate that the primary role of 
TriB may be stimulation of the transporter, while TriA is primarily involved in 
recruitment of the OMF and therefore assembly of the full, functional complex.  
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Our approaches provide a way to further characterize interactions within the complex as 
a whole by purifying either the OMF or the transporter. The ability to purify either 
component allows for a more detailed understanding of how complex interactions are 
stabilized or destabilized by specific mutations. To better understand the interactions 
between TriAB and OMFs, site-specific crosslinking of residues identified through 
sequence homology and modeling could be performed, both with TolC as well as the 
native OMF, OpmH using techniques outlined in Chapter 1. This would provide the 
advantage of elucidating contact interfaces both with the cognate OMF, as well as a 
non-cognate OMF. These results could yield information critical to the assembly of 
these complexes, and provide evidence for a conserved model of MFP-dependent 
transport. Although previous attempts to clone and express OpmH in an E. coli 
background were unsuccessful (Jon Weeks, unpublished), working in the native 
organism P. aeruginosa could yield a more physiologically relevant background for 
experiments. By crosslinking specific identified residues, we can determine the exact 
placement of the MFPs on the OMF, and then by comparing models of RND-MFP 
transporters, determine which MFP interacts with the inter- or intra-protomer grooves of 
the OMF. This could yield further insight into the interfaces between MFPs and their 
transporters and pave the way for development of future inhibitors as well as drug 





Chapter 3. The Bacillus subtilis ABC Transporter YknWXYZ 
3.1 Abstract 
MFPs have been identified as required accessory proteins of transporters found 
in Gram-positive organisms. (Butcher and Helmann 2006) Gram-positive bacteria are 
known to have a single lipid bilayer, whereas Gram-negative bacteria have a dual-
membrane cell envelope. This finding suggests that MFPs play a more defined role in 
the transport process than simply linking the inner and outer membrane components of 
efflux transporters. The ABC-type transporter YknWXYZ in Bacillus subtilis is a 
homolog of the E. coli macrolide efflux complex MacAB-TolC and is known to be 
responsible for resistance against an endogenously produced peptide, SdpC (Lamsa, Liu 
et al. 2012, Yamada, Tikhonova et al. 2012). The SdpC toxin is produced by Bacillus 
cells under starvation conditions in order to lyse surrounding cells and utilize nutrients 
for delay of sporulation, which is a costly and time-consuming process (Fujita, 
Gonzalez-Pastor et al. 2005). The individual components of the complex are YknW, a 
protein of unknown function, YknX, identified as a membrane fusion protein, and 
YknY and YknZ, which together form the ATPase and permease components of the 
transporter, respectively. In this study, I attempt to characterize the function of YknX 
through reconstitution of purified chimeric transporter complexes, in hopes of 
establishing that YknX retains conserved MFP functions associated with other ABC-
type MFP-dependent transporters. I conclude that YknWXYZ is a unique, 4-component 





 The cell envelopes of Gram-positive bacteria are not well understood. While 
Gram-negative and Gram-positive bacteria share some characteristics like the presence 
of phospholipids and peptidoglycan, Gram-positive envelopes are both chemically and 
compositionally distinct (Silhavy, Kahne et al. 2010). 
 
Figure 3.1 – Comparison of Gram-positive and Gram-negative cell envelopes.  
A graphical comparison of Gram-positive and Gram-negative membrane environments. 
Unique features are indicated. LPS – Lipopolysaccharide. LTA – Lipoteichoic acid. 
WTA – Wall teichoic acid.  
 
Generally, Gram-positive envelopes are composed of a cytoplasmic membrane, 
consisting of a phospholipid bilayer which is coated on the outside by a thick layer of 
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peptidoglycan (Puech, Chami et al. 2001, Brennan 2003). Many transporters present in 
Gram-positive bacteria require MFPs for drug resistance, membrane biogenesis, and 
protein secretion, which is intriguing in the context of a single lipid bilayer (Butcher 
and Helmann 2006, Yamada, Tikhonova et al. 2012, Freudl 2013). As the primary roles 
of the MFP have been thought to provide a physical linker between the transporter and 
OMF, recruitment of an OMF, and translation of conformational changes within the 
complex, their requirement is puzzling in the absence of an OMF. Gram-positive MFPs 
are not well studied, but are believed to share the same general 4-domain architecture as 
Gram-negative MFPs based on both homology and secondary structure predictions 
(Zgurskaya, Yamada et al. 2009).  The conservation of the coiled-coil domain in Gram-
positive MFPs is also puzzling, as the domain is proposed to mediate interactions 
between the MFP and OMF. YknWXYZ contains YknX, which is the most studied 
Gram-positive MFP to date (Yamada, Tikhonova et al. 2012, Zgurskaya, Weeks et al. 
2015), but still precious little is known about the function of the complex. Investigation 
of YknWXYZ could yield great insight into the function of MFPs, as well as the 
functional relationship between MFPs and their cognate transporters.  
While MFPs are known to stimulate their cognate transporters, (Zgurskaya, 
Weeks et al. 2015) there are other proposed roles for MFPs, such as substrate binding 
that would make sense in a Gram-positive environment. The E. coli MFP MacA has 
been shown to bind a core LPS molecule, a putative substrate, and other MFPs involved 
in metal export such as ZneB and CusB have been shown to bind zinc and copper, 
respectively (Bagai, Liu et al. 2007, Mealman, Zhou et al. 2012, Lu and Zgurskaya 
2013). Additionally, ZneB has been shown to exhibit structural changes upon zinc 
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binding (De Angelis, Lee et al. 2010). These MFP roles could be reconciled in a Gram-
positive bacterium, and would suggest that like in Gram-negative organisms, MFPs 
have an active role in the transport process that is not yet clearly understood.  
 The B. subtilis protein complex YknWXYZ consists of four interacting 
components known to provide resistance against the endogenously produced toxin, SDP 
(Butcher and Helmann 2006). SDP is the processed form of the SdpC protein, which is 
produced under starvation conditions in Bacillus (Ellermeier, Hobbs et al. 2006). 
Starvation of the organism activates the Spo0A regulon which controls Bacillus entry 
into sporulation, and ultimately controls the sdpABC operon (Molle, Nakaura et al. 
2003). After production, SdpC is then processed into the toxic form, SDP. While the 
details of processing SdpC into the toxin SDP are not known, SdpA and SdpB are both 
required to produce mature SdpC (Perez Morales, Ho et al. 2013). Upon processing and 
export, the extracellular SdpC induces the synthesis of SdpI, an immunity protein that 
protects cells from endogenously produced SdpC. SdpI is produced in the same operon 
as an autorepressor, SdpR. (Ellermeier, Hobbs et al. 2006) 
YknWXYZ is under control of a separate system, the σ-W regulon, which is 
known to be activated as a response to antibiotic exposure (Butcher and Helmann 
2006). Crosslinking experiments indicate that YknX is able to bind YknYZ, and YknW 
is able to interact with YknXYZ (Yamada, Tikhonova et al. 2012). This agrees with the 
current model of MFP-dependent efflux, wherein the MFP interacts directly with the 
transporter, and is involved in the assembly of a larger complex (Zgurskaya, Weeks et 
al. 2015).  However, since the function of YknW remains unknown, it is difficult to 
pinpoint the role of YknW, especially as it relates to OMFs in Gram-negative bacteria. 
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Further complicating our understanding, when YknW is overproduced, it is able to 
provide partial protection against SdpC, but all four components are required for 
complete resistance (Yamada, Tikhonova et al. 2012).  
To investigate this unique Gram-positive MFP-containing complex, we focused 
on finding the primary role of YknX in the complex. Since MFPs are known to 
stimulate their cognate transporters, we first attempted to purify the complex from the 
native organism, B. subtilis and then characterize the ATPase activity of YknY under 
different conditions. We then began chimeric analysis of components of this complex 
with another, more well-studied ABC-type transporter, MacB of E. coli. Such 
component-mixing experiments have been performed in RND-type transporters 
(Krishnamoorthy, Tikhonova et al. 2008), but none with ABC-type transporters from 
such a different background. We investigated interactions between transporters by 
creating fusion proteins, in which the ATPase domains and permease domains of 
YknYZ and MacB were switched, effectively creating hybrid proteins. This was done in 
such a manner that the ATPase domain of MacB would function with the permease 
domain YknZ, and the opposite construct was created as well. In addition, since MacB 
has a short linking peptide between the ATPase and permease domains that is not found 
in either YknY or YknZ, these constructs were created with and without the linking 
region.  
We also cloned and expressed the fusion protein YknYLZ, in which the ATPase 
and permease domains of YknYZ are covalently linked together as a single polypeptide. 
ABC-type transporters extend the ATPase portion of the complex into the cytoplasm of 
the cell, and in MacB, this cytoplasmic domain is directly attached to the permease 
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domain embedded in the membrane. YknYZ, however, is expressed as two distinct 
polypeptides, and the stimulatory activity of YknX on YknY would depend on the 
stability of interactions between both YknX and YknZ, as well as YknZ and YknY, as 
the MFP is proposed to primarily interact with the periplasmic side of any membrane-
bound transporter components. In order to stabilize this complex, YknY and YknZ were 
expressed as a covalently linked complex called YknYLZ wherein the two domains of 
the transporter were linked together via the same flexible linking region from MacB.  
In order to determine if YknX could stimulate the ATPase activity of YknY, this 
fusion protein was purified and tested for ATPase stimulation in the absence and 
presence of complex components. Finally, we also investigated purification and analysis 
of unmodified YknY and YknZ through purification and ATPase assays. 
 
3.3 Results 
3.3.1 YknWXYZ and YknYZ show no intrinsic ATPase activity 
To first establish YknWXYZ as a system to study MFPs in a Gram-positive 
organism, we used the native host, B. subtilis to purify the complex. This purification 
would allow us to obtain YknY, with which we could perform ATPase assays and 
establish the activity of the transporter, as well as establish which complex components 
co-purify with the membrane-bound YknZ permease. For this purpose, B. subtilis 
HB6127 cells were transformed with the shuttle vectors pHCMC04-YknWXYZHis and 
pHCMC04-YknYZHis (Yamada, 2012) and grown according to protocol (Methods). To 
optimize chances of co-purification of complex components, the YknWXYZ 
purification protocol was adopted from the MalFGK2 transporter purification 
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(Landmesser, Stein et al. 2002), which also is an ABC-type transporter and has been 
utilized in similar ATPase assays. The purification protocol for YknYZ was adopted 
from (Yamada, Tikhonova et al. 2012) and solubilized proteins in the detergent Triton 
X-100, which has been used in ATPase assays with previous ABC-type transporters as 
well (Lu and Zgurskaya 2013). Both complexes YknWXYZHis and YknYZHis were 






Figure 3.2 – Purification of Ykn complexes from Bacillus subtilis.  
Membrane fractions of B. subtilis HB6127 cells expressing YknYZ or YknWXYZ 
induced with 0.5% L-xylose were solubilized in 5% Triton X-100 or 1% DDM, 
respectively, and his-tagged proteins were purified from the detergent-soluble fraction 
by Ni2+ affinity chromatography. The column was washed in 5 mM, 15 mM, and 50 
mM steps before elution using 100 mM and 500 mM imidazole. Purified fractions were 




Purification results indicate that YknZ (~42 kDa) can be purified from B. subtilis 
cells, but immunoblotting with anti-YknW antibodies indicated that YknW (24 kDa) 
does not co-purify with YknZ as a complex. Additionally, no YknY (25 kDa) was 
detected in purified YknZHis fractions when visualized using CBB stain (data not 
shown). To establish if the purified proteins retain ATPase activity, purified fractions 
were quantified on 12% SDS-PAGE using a BSA standard and Imagequant analysis 
software before being subjected to an ATPase assay as described in the Methods. E. 
coli-based MacB was also purified according to the YknWXYZ or YknYZ protocols 
and used as a positive control for the ATPase assay. (Figure 3.3) 
 
 
Figure 3.3 – Purified YknWXYZ and YknYZ show no ATPase activity.  































Although results initially indicate ATPase activity for YknYZ, analysis of CBB-
stained fractions showed a significant amount of non-specific proteins (Data not 
shown), and likely do not show ATPase activity intrinsically. Additionally, as 
purification of the whole complex showed no ATPase activity, it seems unlikely that 
YknYZ alone is able to support hydrolysis of ATP. In light of this, new approaches 
were needed to investigate the YknWXYZ complex. 
 Since purification of the complex from the native organism did not yield 
functional proteins, a recombinant system was used to purify the protein from E. coli. 
Several efflux transporters have been shown to have a degree of adaptability, and are 
able to function utilizing other transporter components (Krishnamoorthy, Tikhonova et 
al. 2008)(Chapter 2, Table 2). For instance, certain site-specific mutations allow AcrA 
to function with the non-cognate RND-type transporter MexB (Krishnamoorthy, 
Tikhonova et al. 2008). Additionally, Chapter 1 of this dissertation describes function of 
TriABC with the non-cognate OMF TolC (Table 2). This indicates that efflux 
transporters have a very similar structure, and may be able to function utilizing 
components sourced from other efflux complexes.  
In order to determine if YknWXYZ and ABC-type transporters share the same 
mechanism, we created chimeric proteins between MacB and YknYZ that combine the 
ATPase component of one transporter with the permease component of another (Figure 
3.4). Sequence alignments of an in silico fusion protein where YknY and YknZ are 
connected from the C-terminus of YknY to the N-terminus of YknZ show alignment 
with MacB, however, residues 228-243 within MacB, which lie between the permease 
and ATPase components, do not align with either YknY or YknZ. This is likely a 
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flexible region involved in allowing conformational changes between the two domains. 
In YknWXYZ, when the ATPase and permease regions are expressed separately, there 
would be much less restriction imposed on the interdomain flexibility of the proteins, as 
they are not covalently linked. To determine the requirement of the linker region we 
created our chimera both with and without the region, and attempted to express and 
purify these proteins to determine their ATPase activity.  
Additionally, since co-purification of the entire complex made it difficult to 
determine if YknY co-purified with histidine-tagged YknZ, we also created a fusion 
protein between YknY and YknZ. This fusion protein covalently linked the N-terminus 
of YknY to the C-terminus of YknZ in order to both fix the stoichiometric ratio of the 
two proteins as well as impose a physical connection between the two proteins. Through 




Figure 3.4 – Construction of YknYZ / MacB chimera.  
Top: Topology diagram of MacB (Kobayashi, Nishino et al. 2003). The flexible linker 




Plasmids encoding chimeric proteins were constructed through PCR, in which 
the ATPase-encoding fragment from either pUC-MacB or pHCMCO4-YknWXYZ 
(Table 1) was amplified using an EcoRI restriction site in the forward primer and a 
KpnI site in the reverse primer, and inserted into pUC18 digested with the same 
enzymes. After insertion, the permease fragment was amplified from either pUC-MacB 
or pHCMC04-YknWXYZ using a KpnI forward primer and a SalI reverse primer and 
inserted into the previously constructed plasmid. This insertion of a KpnI site in 
between the ATPase and permease portions of the protein codes for glycine and 
threonine, two uncharged amino acids which are unlikely to affect protein structure. 
Constructs containing the linker region from MacB were created in the same way, 
except MacB primers were designed to amplify through the linker region either at the 
end of the ATPase fragment or starting at the beginning of the permease fragment, 
including the linking region.  
The plasmid encoding the fusion protein linking the ATPase YknY and the 
permease YknZ was also created by PCR. The linking region between the ATPase and 
permease regions of MacB is thought to provide conformational flexibility between the 
two domains, allowing changes needed for function. This same linking region was 
incorporated in between the ATPase and permeases of YknY and YknZ in order to 
provide the same flexibility. pET-YknYLZ was constructed via PCR amplification of 
yknY from B. subtilis 168 genomic DNA using an NcoI-containing forward primer and 
an XhoI-containing reverse primer. The linking region, taken from macB in the E. coli 
genome, was amplified by SalI-containing forward primer and XhoI-containing reverse 
primer. Finally, the permease, yknZ was amplified in the same way as yknY except 
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utilizing SalI-forward and XhoI-reverse primers. The individual fragments were ligated 
into pET21d(+) sequentially. This is possible as SalI and XhoI create compatible 
restriction sites, which upon ligation, create a site which cannot be cleaved by either 
enzyme. This allowed sequential assembly of the plasmid without the utilization of 
multiple restriction sites. 
 
3.3.2 Fusion proteins require a flexible linker for expression 
The resulting plasmids, pUC-MZHis, pUC-MLZHis, pUC-YMHis, and pUC-
YLMHis (Table 1) were transformed into E. coli BL21 (DE3) and cells were grown and 
induced with 1 mM IPTG according to protocol (Methods). The protein MZHis contains 
the ATPase portion of MacB, but without the linking region, followed by the permease 
YknZ. (Figure 3.4) Correspondingly, the MLZHis protein contains the ATPase portion 
of MacB linked to the permease YknZ along with the short linking peptide. YMHis and 
YLMHis follow the same convention, utilizing the ATPase YknY and the permease 
portion of MacB without and with the linking region, respectively. The fusion proteins 
pUC-MLZHis and pUC-YLMHis were shown to express and localize to the membrane, 
however all other fusion proteins were undetectable with either anti-His or anti-MacB 
immunoblotting. (Figure 3.5) This indicates that a fused protein containing both the 
membrane-bound permease and the intracellular ATPase requires this flexible loop 
region in order to be processed and inserted correctly into the membrane. Interestingly, 
it appears that the fusion protein MLZhis reacts strongly with anti-poly His antibody, but 
not anti-MacB antibody, and YLMhis reacts with anti-MacB but not anti-poly His. 
Reasons for this are unclear, as both proteins contain a poly-histidine tag and anti-MacB 
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antibodies are polyclonal, but MLZHis concentrations could be below that of the anti-His 
detection limit, and anti-MacB antibodies could have a tendency to react more with the 
permease domain rather than the ATPase domain. 
 
Figure 3.5 – Expression and localization of chimeric MacB-Ykn constructs.  
C43 cells carrying pUC-based chimeric constructs were grown and protein expressed 
using 1 mM IPTG. After cell lysis, membrane and soluble fractions were separated and 
10 μg of total protein from either the membrane or soluble fraction was separated by 
12% SDS-PAGE gels and visualized by immunoblotting with either anti-poly His or 
anti-MacB antibodies. S – Soluble fraction. M – Membrane fraction. 
 
pET-YLZHis, the construct linking the ATPase and permease regions of the Ykn 
complex was also transformed into E. coli C43 cells, with pET-XHis used as a positive 
control. Protein expression was induced using 1 mM IPTG, and membrane fractions 
were collected. To check YknYLZ localization and expression, both cytoplasmic and 
membrane fractions were resolved by 12% SDS-PAGE and subjected to 
immunoblotting with monoclonal anti-poly His antibody (Sigma). Histidine-tagged 
YknX was used as a positive control. Proteins reacting with monoclonal anti-poly His 
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were detected in both YknX and YknYLZ-expressing membrane fractions, indicating 
that the fusion protein YknYLZ folds correctly and is localized to the membrane of E. 
coli. (Figure 3.6) 
 
Figure 3.6 - YknYLZ expression and localization. 
Anti-his immunoblot showing membrane and soluble fractions of cells carrying pET-
based plasmids expressing proteins. C – Cytoplasmic (soluble) fraction. M – Membrane 
fraction. (-) – Culture not induced. (+) – Culture induced using 1 mM IPTG. 
 
All fusion proteins, including chimeric proteins between MacB and Ykn were 
expressed only when containing the flexible linker region. Thus, the flexible linker is 
required when expressing the ATPase and permease as a single polypeptide. 
Due to this result, we focused efforts solely on the fusion proteins YLZ, MLZHis 
and YLMHis. In order to purify the proteins, we solubilized the membrane fractions of 
C43 cells expressing either MLZHis or YLMHis in Triton X-100 and determined the 





Figure 3.7 – Localization and solubility of the chimeric MLZ and YLM.  
Membrane fractions of C43 cells expressing either MLZHis or YLMHis proteins were 
solubilized in 5% Triton X-100 overnight, and then the insoluble fraction was pelleted 
by centrifugation. The detergent-solubilized, insoluble, and cytoplasmic fractions were 
all separated by 12% SDS-PAGE and visualized by immunoblotting with either anti-
MacB or anti-poly His antibodies.  
 
Immunoblotting revealed that both MLZHis and YLMHis are soluble in Triton X-
100, and that these proteins are localized to the membrane of E. coli. This indicates that 
the proteins have been processed correctly and inserted into the membrane, and may be 
suitable candidates for purification and ATPase assays. 
To establish solubility of YLZ, YknYLZ was expressed in C43 cells at both 37° 
and 16° Celsius for 3 hours and overnight, respectively. By expressing at a lower 
temperature overnight, cells can be kept from reaching the stationary phase, and 
theoretically allowing for production of more protein. After cell growth, membrane 
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fractions were collected, and isolated membranes were incubated overnight in 20 mM 
Tris-HCl, 1 mM PMSF, 10 mM MgCl2, 1 mM ATP-Mg
2+, and either 2% Triton X-100, 
1% DDM, 40 mg/mL LPG, or 1% CHAPS.  
 
 
Figure 3.8 - Detergent screen of YknYLZ.  
Anti-his immunoblot of membrane extracts containing expressed YknYLZ. Cells were 
grown at either 37 or 16 degrees Celsius, membranes were isolated, and the solubilized 
in the indicated detergent. P – Insoluble membrane pellet. S – Soluble membrane 
fraction. 
 
After resolving on a 12% SDS-PAGE and subsequent immunoblotting with anti-
poly His antibody, soluble fractions indicated that YknYLZ has a very low solubility in 
common detergents normally used in screening of membrane proteins, such as Triton 
X-100, CHAPS, and DDM. However, results indicate that YknYLZ is very soluble in 
the less commonly used detergent lysophosphatidylglycerol (LPG).  (Figure 3.8) 
Thusly, LPG was chosen for solubilizing YknYLZ for future experiments. There was no 
observed difference in expression or solubility if the cells were grown at 37° or 16° 
Celsius, and thusly growth conditions were standardized at 37° Celsius with 3 hours of 
induction. 
Having established the expression and solubility of all fusion protein constructs, 
a pilot purification was performed to determine the viability of utilizing the proteins in 
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further biochemical assays. Membrane fractions were collected from cells expressing 
either MLZHis or YLMHis, and solubilized as previously described. After 
ultracentrifugation to pellet the insoluble fraction, proteins were purified from the 
detergent-soluble fraction by Ni2+ affinity chromatography. Fractions were then 
analyzed for protein presence using immunoblotting. (Figure 3.9) 
 
 
Figure 3.9 – Purification of MLZhis and YLMhis.  
Detergent-solubilized membranes were loaded onto a 1 mL Ni-NTA column charged 
with Ni2+. After collecting the flowthrough (FT), the column was washed with binding 
buffer containing 5 mM (5) and 30 mM (30) imidazole. Protein was then eluted using 
100 mM (100) imidazole. After collection, fractions were analyzed using 
immunoblotting for anti-poly His and anti-MacB antibodies.  
 
Analysis of the immunoblots revealed that MLZHis and YLMHis are both able to 
be purified from the membranes of E. coli. However, protein yield and purity were too 
low to be considered for an ATPase assay when fractions were analyzed by staining 
with CBB (Data not shown).  
To increase protein yield, pUC-MLZhis and pUC-YLMhis were subcloned into 
the high-copy plasmid pET-21a (+) which uses a T7 phage promoter rather than the lac-
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based promoter of the pUC plasmids. This was selected to increase protein production, 
which would allow for stronger washing steps, and better overall purification of YLMHis 
and MLZHis. After subcloning, the newly constructed pET-MLZHis and pET-YLMHis 
were transformed into E. coli C43 cells and after protein expression, subjected to the 
same membrane fractionation and solubility assay to determine the localization and 





Figure 3.10 – MLZ and YLM from pET21d are not expressed.  
Plasmids encoding the proteins MLZHis, YLMHis and YknXHis, which was used as a 
positive control were transformed into C43 cells. Cells were induced for 3 hours using 1 
mM IPTG. After cell lysis and membrane fractionation, the membrane fraction was 
solubilized in Triton X-100. Soluble and insoluble fractions were analyzed via SDS-
PAGE and anti-poly His and anti-MacB immunoblotting. C – cytoplasmic fraction. I – 
detergent-insoluble membrane fraction. S – detergent-soluble membrane fraction. 
 
 Unfortunately, no expression from pET-based plasmids was seen for the 
chimeric Mac-Ykn proteins, using either anti-MacB or anti-poly His immunoblotting. 
Hence, pUC-based constructs of MLZ and YLM can be used to obtain protein. 
Having established a method to express chimeric proteins between MacB and 
Ykn, we set out to purify YknYLZ. As a positive control we also purified MacB, which 
has been previously used in experiments to characterize ATPase activity (Lu and 
Zgurskaya 2012). For this purpose, the plasmids pET-X, pET-YLZ, and the positive 
control pET-MacB (Table 1) were transformed into E. coli C43 cells. After growth and 
protein expression, membrane fractions from the cells were collected. YknYLZ was 
solubilized in LPG, whereas YknX and MacB were solubilized in Triton X-100. Next, 
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solubilized membranes were loaded onto a Ni-NTA column charged with Ni2+, and 





Figure 3.11 – Purification profiles of YknYLZ, YknX, and MacB.  
Total membranes of C43 cells expressing various constructs were solubilized in either 
5% Triton X-100 or 20 mg/mL LPG. The detergent-soluble fraction was loaded onto 
Ni2+ charged NTA column and bound proteins were eluted with the indicated imidazole 
concentrations. Fractions were resolved by 12% SDS-PAGE and visualized with CBB. 
A. Purification profile of YknYLZ. B. Purification profile of YknX. C. Purification 




After purification, fractions were checked for the presence of purified protein 
using standard SDS-PAGE, and then fractions containing purified protein were 
combined and dialyzed to remove contaminating buffer components. As a control, a 
portion of purified MacB and YknX were then transferred into LPG as described in the 
Methods section.  
Having purified and established concentrations of purified proteins, we then 
performed an ATPase assay to determine the ability of YknYLZ to bind and hydrolyze 
ATP, as well as the ability of YknX to have an effect on ATP hydrolysis rates. In the 
assay, purified proteins were mixed according to protocol with reaction buffer, and 
incubated at 37° Celcius (Tikhonova, Devroy et al. 2007). At 4 minute intervals, 
aliquots of 1 μL were removed from the reaction mixture and placed into stop solution. 
In addition to previously mentioned proteins and detergent mixtures, a previously 
purified MacB stored in glycerol was used as a positive control for technique, in both 
LPG and TX-containing buffers. Once the time course was completed, aliquots were 
spotted on a TLC plate and amounts of hydrolyzed ATP were quantified using a 
Phosphoimager and ImageQuant. ATPase activity was recorded as a function of nmol 
ATP / min / mg protein. We found that the ATPase activity of MacB is severely 
inhibited by the presence of the detergent LPG. (Figure 3.12) This is likely due to the 
ionic nature of LPG, as compared to Triton X-100, which is a non-ionic detergent.  
Experiments to exchange LPG for Triton X-100 were performed by binding 
YknYLZ to an affinity column and running large volumes of Triton-containing wash 
buffer over the protein before elution were unsuccessful. (Data not shown) 
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Additionally, no stimulation of ATPase activity was observed upon addition of YknX to 
either MacB or YknYLZ, regardless of detergent conditions. (Data not shown) 
 
 
Figure 3.12 - LPG inhibits ATPase activity of purified MacB.  
ATPase rates of MacB and YknYLZ purified from E. coli. Proteins with the suffix 
“TX” are solubilized in Triton X-100, and proteins with the suffix “LPG” are 
solubilized in the anionic detergent LPG. 
 
 Since YknYLZ is insoluble in most common detergents, and the only found 
detergent that solubilizes the protein is shown to inhibit ATPase activity, further 
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3.3.3 – YknY localizes to the membrane fraction. 
Previous results in this and other publications (Yamada, Tikhonova et al. 2012) 
made it difficult to determine if YknY co-purified with his-tagged YknZ in either 
YknWXYZ or YknYZ purifications. In previous studies, a ~50 kDa band was observed 
in purifications with YknZ co-expressing YknY (Yamada, Tikhonova et al. 2012). This 
could correspond to a dimeric YknY, which had a predicted monomeric size of 25.3 
kDa. However, our efforts yielded no positive confirmation of YknY being purified 
with other complex components, likely due to being below the detection limit. Adding a 
tag and then purifying YknY would facilitate both the ability to detect the protein using 
immunoblotting as well as the ability to pull on the complex from another component. 
By purifying YknY, we can determine if YknY alone is sufficient for ATPase activity, 
or we can determine if a complex of YknYZ is required. To facilitate this, a strep-tag 
was cloned onto the N-terminus of YknY in the shuttle vector pHCMC04-YknYZHIs. 
The N-terminus of the protein was chosen for the tag due to the structure of the ATPase, 
in which the active regions of the protein are localized to the C-terminal region. By 
placing the tag on the opposite side of the protein, chances of the tag interfering with 
functionality were minimized. After construction of the plasmid, cells were transformed 
with the newly constructed plasmid, and expression and localization of the protein was 





Figure 3.13 – YknStrepYZHis expresses YknY but not YknZ.  
B. subtilis HB6127 cells carrying two different clones of StrepYZHis were induced using 
0.5% L-xylose, lysed and subjected to membrane fractionation. 50 μg of protein was 
loaded onto 12% SDS-PAGE and subjected to anti-strep and anti-poly His 
immunoblotting.  
 
Immunoblotting results show a clear band running just above the predicted 
monomeric MW of 25 kDa for YknY, however no bands appear on an anti-poly His 
immunoblot despite an overwhelmingly large amount of total protein loaded. The 
absence of expression of YknZ is puzzling, as the PCR product for cloning was 
amplified from the YknZ-expressing pHCMC04-YknYZHis and no changes were made 
near the overlapping YknY-YknZ stop / start codon. One explanation is that expression 
has been disrupted by downstream effects of the introduction of the strep-tag.  
To take a different approach in the purification of YknY, we chose to utilize the 
plasmid pET-YknYHis and purify YknY alone and utilize it in ATPase assays with other 
complex components. As YknY is not predicted to have any transmembrane segments, 
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we first needed to check the localization and expression of the protein encoded by the 
pET-YknYHis plasmid. Since it is possible that YknY could exist in either the soluble or 
membrane fractions, as well as form inclusion bodies, after cell lysis, we pelleted 
unbroken cells via low-speed centrifugation, and then before pelleting membrane 
fractions at >100,000 xg, we pelleted inclusion bodies via centrifugation at 25,000 xg 
for 1 hour. (DeLisa, Lee et al. 2004) After isolation, fractions were analyzed by 
immunoblotting. (Figure. 3.14)  
 
 
Figure 3.14 – Localization and expression of pET-YknYHis.  
E. coli cells carrying pET-based YknY constructs were induced using 1 mM IPTG and 
expressed empty vector (-) or YknYHis (+). Cells were lysed and subjected to low-speed 
centrifugation, then increasing speeds to pellet inclusion bodies and membrane fractions 
before fraction analysis with anti-poly His immunoblotting. WC – whole cell lysate.  
 
Results indicate that YknYHis is expressed from pET21-d plasmid, and localizes 
broadly, with roughly equal amounts detected in inclusion bodies as well as membrane 
fractions. Slightly less YknY was observed in the soluble fraction of the cell.  
Due to the complications of purifying protein from inclusion bodies, including 
the requirements of unfolding and refolding the protein (Palmer and Wingfield 2004), 
we chose to purify YknYHis from the membrane fraction of E. coli. Cells were grown 
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and protein expressed according to protocol (Methods), and the membranes solubilized 
with 5% Triton X-100. Protein was purified using Ni2+ affinity chromatography. 
Fractions were analyzed by SDS-PAGE and staining with CBB. (Figure. 3.15) 
 
 
Figure 3.15 – Purification of YknYHis.  
E. coli cells carrying pET-YknYHis were induced using 1 mM IPTG, subjected to lysis 
and membrane fractionation, and His-tagged proteins purified using Ni2+ affinity 
chromatography with increasing amounts of imidazole. YknY can be seen purified, 
running at an expected MW of ~25 kDa.  
 
Purification results were mixed, as YknY was readily purified from the 
detergent-soluble membrane fraction, but fractions contained a significant amount of 
contamination. Additionally, a strong band of approximately ~45 kDa can be seen in 
most fractions, and very strongly in elution fractions. This could be a YknY dimer, 
which has an expected MW of ~50 kDa. The stability of the YknY dimer seems to be 
strongest in purified protein, as these bands were not observed in previous experiments 
utilizing whole membrane fractions. From this, we can conclude that YknY is expressed 





 MFPs have been implicated in Gram-positive transport systems, indicating that 
they have an active role in the transport process that extends beyond simply linking two 
membrane transport components (Harley, Djordjevic et al. 2000). While we know that 
they are involved in recruitment of OMFs and that they display a range of 
conformational flexibility, neither of these facts reconciles their presence in a Gram-
positive environment. The only currently defined role for MFPs applicable in a Gram-
positive organism would be to stimulate a cognate transporter. In order to further 
identify how MFPs stimulate the ATPase component of transporters, we chose to 
express, purify, and reconstitute the YknWXYZ transporter in various ways that would 
determine if YknX is able to stimulate its cognate ATPase, YknY. 
 Initially, purification of the transporter from the native organism, B. subtilis was 
attempted. YknWXYZ and YknYZ were purified, each with a histidine tag on YknZ, 
relying on co-purification of other complex components. Purification of YknWXYZ 
showed that YknZ is readily purified from the native organism, but in contrast to 
published results, YknW does not co-purify with YknZ. Previous data showed that 
YknW will co-purify only in the presence of YknXYZ, but immunoblotting analysis of 
the purification profile shows YknW largely in the flow-through fraction. This 
discrepancy can be explained in that purification conditions described here differ from 
published methods (Yamada, Tikhonova et al. 2012) in a few specific ways. Firstly, the 
oligomerization profile of YknW can change based on if the column was charged with 
Cu2+, indicating that a column used here, charged with Ni2 could alter the oligomeric 
state, and thus functionality of YknW. Additionally, membrane fractions were 
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solubilized in DDM rather than Triton X-100 which could potentially affect interactions 
between complex components. Either of these changes individually have the potential to 
negatively affect complex affinity, and together, are likely the source of discrepancies 
between published results and the results seen here. Further investigation of purifying 
the YknWXYZ complex from B. subtilis would require optimization of purification 
procedures. 
Purification of YknYZ also yielded YknZ in relatively large amounts, but no 
YknY could be detected using CBB or silver staining. When YknZ-containing fractions 
from purification were collected, concentrated, and subjected to ATPase assays, YknYZ 
showed ATPase activity, but the purification was not of sufficient purity to conclude 
that the observed ATPase activity was a result of YknY. Any contaminating non-
specific ATPases could drastically skew results, and the lack of activity in the 
YknWXYZ purification indicates that the activity seen in YknYZ was non-specific, as 
it seems unlikely that purifying YknYZ in the presence of YknW and YknX would 
render the complex inactive. Purifications could be investigated further to obtain pure 
YknY, and could include further purification steps such as gel-filtration 
chromatography. The lack of ATPase activity in the purified YknWXYZ fractions could 
be due YknY not co-purifying with YknZHis, or a more complex explanation, such as 
YknYZ being a very slow ATPase, an intrinsic instability of the complex, or other 
component requirements for ATPase activity of the transporter. 
 In order to establish a system in which to study YknX, we created chimeric 
proteins that combine the ATPase of either MacB or YknYZ with the permease of the 
opposite protein. Chimeric proteins would also offer insight into the mechanism of 
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ATPase stimulation by MFPs, as chimeric proteins may be stimulated by one, both, or 
neither cognate MFP.  
 Chimeric proteins were constructed between E. coli MacB and B. subtilis 
YknYZ, with and without a flexible linker region contained between the ATPase and 
permease regions of MacB. A fusion protein consisting of YknY covalently linked to 
YknZ was also created, also with a flexible linker region. Upon expression analysis, 
proteins containing the flexible loop region were expressed in E. coli and found to 
localize to the membrane, including MLZ, YLM, and MLZ. Thus, when the ATPase 
and permease of these chimeric transporters are covalently linked together, a flexible 
linker region is required for proper expression and localization to the membrane. This 
linker region likely imparts structural flexibility to the protein, and allows 
conformational changes needed for transport. This is consistent with MacB, which 
contains this linking region, and suggests that when the ATPase and permease 
components of efflux transporters are expressed as a single polypeptide, the linking 
region is required to allow movement of the domains relative to one another. 
After expression analysis, these proteins were purified from solubilized 
membrane extracts and analyzed for contaminating proteins. Upon analysis, it was 
determined that the purity of samples coming from membranes expressing YLM and 
MLZ were not sufficient to use in ATPase assay. Purification protocols were optimized, 
however protein was still unable to be collected in a sufficient quantity and purity for 
assays.  
In order to improve expression of protein, YLM and MLZ were sub-cloned into 
a high-copy plasmid, however both YLM and MLZ were found to not express from 
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pET-based plasmids. These plasmids were sequenced, and contained no mutations or 
unexpected sequences, so their lack of expression is confusing. It is possible that by 
changing the restriction site upstream of the start codon, expression was limited by 
inductive effects. While YLM and MLZ purifications expressed from pUC-based 
plasmids could be optimized with larger culture volumes and more stringent 
purification steps such as gel-filtration chromatography, it was determined that the most 
effective method to determine the conserved features of YknX would be to investigate it 
alongside YLZ. In the future, YLM and MLZ could both be investigated further, and 
purified from a pUC-based expression vector. 
After creation of the YknYLZ fusion protein, expression analysis and membrane 
fractionation showed that YknYLZ is expressed and localized to the membrane of E. 
coli. Unfortunately, upon solubility tests, it was shown that YknYLZ is largely 
insoluble in the common non-ionic detergent Triton X-100. To solubilize and purify 
YknYLZ, an exotic detergent LPG was used. However, upon analysis, it was shown 
that a control sample of MacB solubilized and purified in Triton X-100 showed an 
ATPase rate of 38.9 nmol ATP / min / mg protein, but the same sample of MacB 
solubilized and purified in LPG was unable to support ATPase activity. Thus, it seems 
likely that ionic interactions between the detergent LPG and the protein prevent active 
hydrolysis of ATP for both MacB and YknYLZ. Harsher detergents can interfere with 
protein structure, rendering some inactive. Non-ionic detergents are typically less likely 




Pursuant to our goal of obtaining pure YknY to study through ATPase assays, 
we chose to place a tag on YknY and purify the ATPase component of the transporter 
directly. A strep-tag was placed on the N-terminus of YknY in order to facilitate this 
purification. The N-terminus of the protein was chosen because the ATP-hydrolyzing 
domains of the protein are located at the C-terminal end of YknY, and placing a tag on 
the opposite end of the protein reduces chances that the tag would interfere with protein 
function. The strep-tagged YknY was expressed alongside his-tagged YknZ, but only 
YknY was detectable through immunoblotting. The loss of expression of YknZ is 
puzzling, as the only changes made on the construct were on the 5’-end of YknY, and 
no changes were made near YknZ-encoding regions of the plasmid. One possible 
explanation is downstream inductive effects from changes on YknY.  
The E. coli-based pET-YknY plasmid was used to express the protein and 
determine if YknY could be purified in sufficient quantity and purity for ATPase 
assays. Localization checks indicated that YknY is present in roughly equal amounts in 
the membrane fraction and in inclusion bodies, and a lower amount of the protein is 
localized to the cytoplasmic fraction of the cell. Since YknY is predicted to associate 
with the membrane, it was decided to purify YknY from the membrane fraction of the 
cell, especially because ATPase assays would require the mixing of YknY with 
detergent-solubilized membrane proteins also purified from the membrane fraction. 
Unfortunately, while YknY purification yielded a large amount of the protein, seen both 
in monomeric and dimeric forms, fractions contained a large amount of contaminants, 
and further efforts are needed to optimize purifications. 
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 YknX is the only characterized Gram-positive MFP to date, but no conserved 
MFP functions have been associated with it or YknWXYZ. In order to characterize the 
identity of YknX as a conserved, functional MFP in a Gram-positive organism, we took 
approaches to establish that YknX can stimulate the ATPase activity of YknY, just as 
MacA can stimulate the ATPase activity of its cognate transporter, MacB. 
Unfortunately, the YknWXYZ complex presented many difficulties in terms of 
purifying and isolating proteins for further study. The chimeric fusion proteins YLM 
and MLZ both expressed when cloned into pUC-based vectors, but not in pET-based 
plasmid backgrounds. Further investigation into purification of both these chimeric 
proteins could be continued in pUC-based vectors, rather than the non-expressing pET-
based constructs, and more stringent purification procedures could yield protein in 
sufficient purity and quantity for ATPase assays. While other complex components 
would be based in a different plasmid background, purified proteins could still be mixed 
together and studied to determine if these chimeric proteins are able to be stimulated by 
other complex components such as YknX, MacA, and YknW. Additionally, the fusion 
protein YknYLZ could be re-investigated utilizing a broader detergent screen, possibly 
providing conditions under which the protein can be solubilized and tested. Detergents 
should be selected based on their overall charge, with a preference for non-ionic 
detergents that would likely not interfere with ATPase assays.  
 Purifications of proteins from the native organism could also be re-visited, 
utilizing optimized purification protocols, as well as adding additional purification steps 
such as gel-filtration chromatography. It would be useful to develop anti-YknY 
antibodies to determine if the ATPase component of the transporter is definitively able 
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to co-purify with other transporter components. If indeed YknY is able to co-purify with 
YknZ, and samples can be purified in sufficient quantity and purity, then it would be 
feasible to combine complex components in ATPase assays and determine the ATPase 
activity and stimulation of YknY, purified either from YknWXYZ or YknYZ. 
Additionally, YknY purifications could yield this same result, and YknY purifications 
could be attempted from other fractions of the cell, such as inclusion bodies or the 
cytoplasmic fraction.  
 While there is no clear evidence that SdpC is the substrate of the YknWXYZ 
complex, (Yamada, Tikhonova et al. 2012) it is also possible that addition of SdpC to 
ATPase assays could have an effect on the ATP hydrolysis rate of the transporter. This 
would be a difficult proposal due to the small size of SdpC, (42 amino acids) but 
plasmid constructs exist that express SdpC in B. subtilis and it can be isolated using 
TCA precipitation (Yamada, Tikhonova et al. 2012). Further investigation into the 
viability of utilizing SdpC in reaction buffers would be required to determine if it has 
any possible effect on the transporter.  
 While the YknWXYZ transporter presented significant difficulties in 
characterizing conserved MFP functions, as well as determining ATPase activity of the 
proposed transporter, there is still much to be learned about Gram-positive MFP-
dependent transporters. The further investigation of an ABC-type transporter from such 
a unique background would provide insight into the conserved functions of MFP-
dependent transporters, as a large amount of the research done today concerns Gram-
negative, RND-type transporters. Furthering our knowledge of how these transporters 
assemble and function across multiple families and species will allow for more 
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intelligent drug design in the future, as well as pave the way for inhibitors that could 
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Appendix A: List of primers 





YfwdNdeI  CTAGCATATGATTCAGCTTTCTAATGTGCG  
ZrevXhoI  CTAGCTCGAGCTCATAACGCAGCGC  
MacBfwdNdei  CTAGCATATGACGCCTTTGCTCG  















fyknYZNcoI  GACTCCATGGCCATTCAGCTTTC 
ryknYXhoI  GAATTCTCGAGTTCTCCCACACTCC 
fLinkerSalI  GTATTATGTCGACCGCAATCCTCCCGCCATTG 
rLinkerXhoI  GGCGGCTCGAGGTTAAAACCGCTGACAAAC 
fyknZSalI  GACGGCGTCGACTTGGAAAACATCAG 





A26rev  CGATCATATGTGGCCCGGATGGAGC  
A47rev  CGATCATATGATGACCACCTTCTCGCTGGC  
Actermfwd  ACTGCATATGAAGCCGTTTTCCCTCGCC  
B9rev  CGATCATATGCCGGGCTTGAGGC  
B30rev  CGATCATATGATCACCACCTGGCGTTCG  
Bctermfwd  ACTGCATATGAAGGGCGGTTTCAACC  
Axctermfwd  ACTGACTAGTGGCAACTCTAGAGGAGGCGACG  
Ax26rev  CAGTACTAGTCTGGCCCGGATGGAGC  
 
148 
Ax47rev  CAGTACTAGTGATGACCACCTTCTCGCTGGC  










TriC PciI FWD  GACCACATGTACAAGGGCGGTTTCGGCCTG 
TriC-His HindIII Rev CGTGCTAAGCTTCAATGATGATGATGATGATGGC
GTCCCGGTTCCGGAATC 
TriA SacI FWD  TTAGGAGCTCAGGAGGAATTCACCATGTCAGACG
CCAGAGGCGC 


























































TolC NcoI FWD  AATTCCATGGCCAAGAAATTGCTCCCCATTCTTAT
CGG 
TolC-His HindIII  GCTCTAGAAGCTTAGTGATGGTGATGGTGATGGT
TACGGAAAGGGTTATGACC 
PA glmS Up  GCACATCGGCGACGTGCTCTC 
PA glmS Down  CTGTGCGACTGCTGGAGCTGA 
 
